

# A Randomized, Controlled Trial of 3.0 mg of Liraglutide

New England Journal of Medicine

373, 11-22

DOI: [10.1056/nejmoa1411892](https://doi.org/10.1056/nejmoa1411892)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Liraglutide: A New Option for the Treatment of Obesity. <i>Pharmacotherapy</i> , 2015, 35, 926-934.	2.6	99
3	Obesity medications. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 360-366.	2.3	15
4	The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes. <i>Practical Diabetes</i> , 2015, 32, 297.	0.3	16
5	Anti-obesity drugs. <i>Current Opinion in Lipidology</i> , 2015, 26, 536-543.	2.7	23
6	Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists. <i>Journal of Korean Diabetes</i> , 2015, 16, 252.	0.3	0
7	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 1403-1414.	2.1	22
8	Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?. <i>Current Vascular Pharmacology</i> , 2015, 14, 76-79.	1.7	7
10	Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. <i>Canadian Journal of Diabetes</i> , 2015, 39, S134-S141.	0.8	17
11	Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy. <i>Current Opinion in Pharmacology</i> , 2015, 25, 23-29.	3.5	7
12	Obesity Education Strategies for Cancer Prevention in Women's Health. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 249-258.	0.8	7
13	European Guidelines for Obesity Management in Adults. <i>Obesity Facts</i> , 2015, 8, 402-424.	3.4	2,172
14	Another Agent for Obesity – Will This Time Be Different?. <i>New England Journal of Medicine</i> , 2015, 373, 82-83.	27.0	16
15	Liraglutide in obesity: a guide to its use in the EU. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 334-340.	0.6	0
16	Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants. <i>Evidence-Based Medicine</i> , 2015, 20, 203-203.	0.6	0
17	Liraglutide in Weight Management. <i>New England Journal of Medicine</i> , 2015, 373, 1779-1782.	27.0	12
18	Liraglutide – another weapon in the war against obesity?. <i>Nature Reviews Endocrinology</i> , 2015, 11, 569-570.	9.6	8
19	Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 687.	7.4	707
20	Pharmacotherapy for the management of obesity. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1376-1385.	3.4	94

#	ARTICLE	IF	CITATIONS
21	Lorcaserin Hcl for the treatment of obesity. Expert Opinion on Pharmacotherapy, 2015, 16, 2531-2538.	1.8	25
22	Effects of Liraglutide 3.0 Mg on Weight and Risk Factors in Hispanic Versus Non-Hispanic Populations: Subgroup Analysis from Scale Randomized Trials. Endocrine Practice, 2016, 22, 1277-1287.	2.1	17
23	Metabolic Inflammation-Differential Modulation by Dietary Constituents. Nutrients, 2016, 8, 247.	4.1	77
24	Hypoglycemic agents and potential anti-inflammatory activity. Journal of Inflammation Research, 2016, 9, 27.	3.5	83
25	The Use of Rat and Mouse Models in Bariatric Surgery Experiments. Frontiers in Nutrition, 2016, 3, 25.	3.7	40
27	Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World Journal of Diabetes, 2016, 7, 572.	3.5	51
28	Glucagon-like peptide-1 drives energy metabolism on the synaptic highway. FEBS Journal, 2016, 283, 4413-4423.	4.7	19
29	Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism, 2016, 24, 51-62.	16.2	198
30	Adenylate cyclase 3: a new target for anti-obesity drug development. Obesity Reviews, 2016, 17, 907-914.	6.5	35
31	The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. Obesity Reviews, 2016, 17, 553-572.	6.5	33
32	Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function. Journal of Cellular Physiology, 2016, 231, 756-767.	4.1	37
33	Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. British Journal of Clinical Pharmacology, 2016, 81, 613-620.	2.4	48
34	Why the NHS should do more bariatric surgery; how much should we do?.. BMJ, The, 2016, 353, i1472.	6.0	78
35	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes, Obesity and Metabolism, 2016, 18, 558-570.	4.4	134
36	Hidden Obesity in Dialysis Patients: Clinical Implications. Seminars in Dialysis, 2016, 29, 391-395.	1.3	12
37	Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial. EBioMedicine, 2016, 13, 190-200.	6.1	108
38	American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice, 2016, 22, 842-884.	2.1	162
39	American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice, 2016, 22, 1-203.	2.1	952

#	ARTICLE	IF	CITATIONS
40	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	2.1	405
41	Management of Obesity. <i>Journal of Clinical Oncology</i> , 2016, 34, 4295-4305.	1.6	50
42	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. <i>Journal of Clinical Oncology</i> , 2016, 34, 4203-4216.	1.6	277
43	Pharmacological options for managing type 2 diabetes. <i>NursePrescribing</i> , 2016, 14, 330-338.	0.1	0
44	Harveian Oration 2016: Some observations on the causes and consequences of obesity. <i>Clinical Medicine</i> , 2016, 16, 551-564.	1.9	13
45	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. <i>Cell Reports</i> , 2016, 17, 2845-2856.	6.4	22
47	Reappraisal of GIP Pharmacology for Metabolic Diseases. <i>Trends in Molecular Medicine</i> , 2016, 22, 359-376.	6.7	128
48	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1398-1405.	2.3	35
49	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 1236-1242.	1.2	59
50	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. <i>Current Atherosclerosis Reports</i> , 2016, 18, 36.	4.8	13
51	Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. <i>Translational Psychiatry</i> , 2016, 6, e809-e809.	4.8	60
52	Liraglutide 3.0mg for Weight Management: A Population Pharmacokinetic Analysis. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1413-1422.	3.5	30
53	The metabolic vascular syndrome - guide to an individualized treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 5-17.	5.7	29
55	Perspectives in GLP-1 Research: New Targets, New Receptors. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 427-438.	7.1	61
56	Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. <i>Postgraduate Medicine</i> , 2016, 128, 364-370.	2.0	19
57	Proactive and Progressive Approaches in Managing Obesity. <i>Postgraduate Medicine</i> , 2016, 128, 21-30.	2.0	6
58	Long-term effects of gastric bypass surgery on psychosocial well-being and eating behavior: not all that glitters is gold. <i>Acta Clinica Belgica</i> , 2016, 71, 395-402.	1.2	7
60	Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. <i>Age</i> , 2016, 38, 485-493.	3.0	10

#	ARTICLE	IF	CITATIONS
61	Can we win the war on obesity with pharmacotherapy?. Expert Review of Clinical Pharmacology, 2016, 9, 1289-1297.	3.1	10
62	GLP-1 as a target for therapeutic intervention. Current Opinion in Pharmacology, 2016, 31, 44-49.	3.5	32
64	Current drugs for weight loss. Practical Diabetes, 2016, 33, 229-232.	0.3	0
65	An update on naltrexone/bupropion extended-release in the treatment of obesity. Expert Opinion on Pharmacotherapy, 2016, 17, 2235-2242.	1.8	10
66	Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. International Journal of Cardiology, 2016, 219, 293-300.	1.7	17
67	Obesity in patients with HIV infection: epidemiology, consequences and treatment options. Expert Review of Endocrinology and Metabolism, 2016, 11, 395-402.	2.4	5
68	Pharmacotherapy for Obesity. Endocrinology and Metabolism Clinics of North America, 2016, 45, 521-538.	3.2	28
69	Drugs to treat obesity: do they work?. Postgraduate Medical Journal, 2016, 92, 401-406.	1.8	11
70	Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes, Obesity and Metabolism, 2016, 18, 1217-1225.	4.4	39
71	Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clinical Obesity, 2016, 6, 233-242.	2.0	22
72	Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity and Metabolism, 2016, 18, 491-499.	4.4	52
73	Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus. Internal Medicine Journal, 2016, 46, 540-549.	0.8	4
74	Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus. Journal of Diabetes Investigation, 2016, 7, 56-63.	2.4	27
75	Glucagon-like peptide-1: The missing link in the metabolic clock?. Journal of Diabetes Investigation, 2016, 7, 70-75.	2.4	23
76	Weight maintenance: challenges, tools and strategies for primary care physicians. Obesity Reviews, 2016, 17, 81-93.	6.5	72
77	Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2016, 176, 1474.	5.1	81
78	Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs, 2016, 25, 1167-1179.	4.1	16
79	GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2125-2132.	2.4	24

#	ARTICLE	IF	CITATIONS
81	Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. , 2016, , 231-260.		0
83	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	8.6	113
84	Cardiovascular Effects of the New Weight Loss Agents. Journal of the American College of Cardiology, 2016, 68, 849-859.	2.8	22
85	Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabetes. Medical Hypotheses, 2016, 95, 5-9.	1.5	18
86	Liraglutide, GLP-1 receptor agonist, for chronic weight loss. Expert Review of Endocrinology and Metabolism, 2016, 11, 373-378.	2.4	3
87	Role of glucagon-like peptide 1 receptor agonists in management of obesity. American Journal of Health-System Pharmacy, 2016, 73, 1493-1507.	1.0	41
88	Obesity and Management of Weight Loss. New England Journal of Medicine, 2016, 375, 1187-1189.	27.0	8
89	Robust anti-obesity and metabolic effects of a dual <scp>GLP</scp>â€¹/glucagon receptor peptide agonist in rodents and nonâ€‘human primates. Diabetes, Obesity and Metabolism, 2016, 18, 1176-1190.	4.4	185
90	Pharmacological Approaches in the Treatment and Maintenance of Weight Loss. Diabetes Care, 2016, 39, S260-S267.	8.6	37
91	Pharmacotherapy in Treatment of Obesity. Gastroenterology Clinics of North America, 2016, 45, 663-672.	2.2	9
92	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics, 2016, 12, 1.	3.0	0
93	A Plethora of GLP-1 Agonists: Decisions About What to Use and When. Current Diabetes Reports, 2016, 16, 120.	4.2	17
94	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. Expert Review of Endocrinology and Metabolism, 2016, 11, 475-499.	2.4	16
95	Early Weight Loss with Liraglutide 3.0 mg Predicts 1â€‘Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity, 2016, 24, 2278-2288.	3.0	88
97	Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ, The, 2016, 355, i5340.	6.0	13
98	Patient-Centered Care of the Patient with Obesity. Endocrine Practice, 2016, 22, 9-10.	2.1	2
99	Gut hormones and gastric bypass. Cardiovascular Endocrinology, 2016, 5, 69-74.	0.8	3
100	Bariatric surgery and remission of type 2 diabetes mellitus. Current Opinion in Lipidology, 2016, 27, 97-98.	2.7	1

#	ARTICLE	IF	CITATIONS
101	Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 430-435.	4.4	27
102	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1183-1195.	3.4	86
104	The Cardiovascular Biology of Glucagon-like Peptide-1. <i>Cell Metabolism</i> , 2016, 24, 15-30.	16.2	443
105	The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight. <i>Current Atherosclerosis Reports</i> , 2016, 18, 49.	4.8	19
106	Targeting adipose tissue in the treatment of obesity-associated diabetes. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 639-660.	46.4	518
107	Incretin hormone receptors are required for normal beta cell development and function in female mice. <i>Peptides</i> , 2016, 79, 58-65.	2.4	10
108	Obesity and diabetes mellitus in the Arab world. <i>Journal of Taibah University Medical Sciences</i> , 2016, 11, 301-309.	0.9	24
109	Role of Bupropion Plus Naltrexone for the Management of Obesity. <i>Journal of Pharmacy Technology</i> , 2016, 32, 125-132.	1.0	4
110	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2424.	7.4	614
111	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 357-371.	4.7	12
112	Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism. <i>Current Opinion in Lipidology</i> , 2016, 27, 257-263.	2.7	27
113	The intersection of nonalcoholic fatty liver disease and obesity. <i>Science Translational Medicine</i> , 2016, 8, 323rv1.	12.4	60
114	6. Obesity Management for the Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, S47-S51.	8.6	95
115	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. <i>Journal of Psychopharmacology</i> , 2016, 30, 227-236.	4.0	37
116	Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. <i>Current Atherosclerosis Reports</i> , 2016, 18, 7.	4.8	2
117	Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. <i>International Journal of Obesity</i> , 2016, 40, 1310-1319.	3.4	266
118	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 29.	6.8	42
119	Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 116-118.	1.5	18

#	ARTICLE	IF	CITATIONS
120	Weight management in obesity – past and present. <i>International Journal of Clinical Practice</i> , 2016, 70, 206-217.	1.7	74
121	Central nervous system regulation of eating: Insights from human brain imaging. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 699-713.	3.4	132
122	A Comparison of New Pharmacological Agents for the Treatment of Obesity. <i>Annals of Pharmacotherapy</i> , 2016, 50, 376-388.	1.9	18
123	Management of obesity. <i>Lancet, The</i> , 2016, 387, 1947-1956.	13.7	715
124	GLP-1 based therapies: clinical implications for gastroenterologists. <i>Gut</i> , 2016, 65, 702-711.	12.1	34
125	Emerging Therapies for Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2016, 20, 365-385.	2.1	8
126	Medical management of obesity in Scandinavia 2016. <i>Obesity Medicine</i> , 2016, 1, 38-44.	0.9	14
127	FDA-Approved Anti-Obesity Drugs in the United States. <i>American Journal of Medicine</i> , 2016, 129, 879.e1-879.e6.	1.5	119
128	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 92-107.	2.5	35
129	Advances in managing obesity. <i>Nature Reviews Endocrinology</i> , 2016, 12, 65-66.	9.6	14
130	Best (but oft-forgotten) practices: sensitivity analyses in randomized controlled trials. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 5-17.	4.7	42
131	GLP-1 and Amylin in the Treatment of Obesity. <i>Current Diabetes Reports</i> , 2016, 16, 1.	4.2	56
132	An overview of new GLP-1 receptor agonists for type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 145-158.	4.1	41
133	Current Perspectives on Long-term Obesity Pharmacotherapy. <i>Canadian Journal of Diabetes</i> , 2016, 40, 184-191.	0.8	16
134	Medical Management of Diabetes: Do We Have Realistic Targets?. <i>Current Diabetes Reports</i> , 2017, 17, 4.	4.2	44
135	Mechanisms, Pathophysiology, and Management of Obesity. <i>New England Journal of Medicine</i> , 2017, 376, 254-266.	27.0	1,145
136	Liraglutide for weight management: a critical review of the evidence. <i>Obesity Science and Practice</i> , 2017, 3, 3-14.	1.9	184
138	Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 284-295.	1.5	54



#	ARTICLE	IF	CITATIONS
139	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 387-396.	2.4	16
140	Nanogel-based nasal ghrelin vaccine prevents obesity. <i>Mucosal Immunology</i> , 2017, 10, 1351-1360.	6.0	43
141	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 389, 1399-1409.	13.7	502
142	GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 401-408.	3.1	51
143	Effects of once-a-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1242-1251.	4.4	271
144	Glucagon-like peptide-1 agonists for weight loss in people with obesity. <i>Obesity Medicine</i> , 2017, 5, 29-43.	0.9	0
145	Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain—Adipocyte Axis. <i>Drugs</i> , 2017, 77, 493-503.	10.9	32
146	White Paper AGA: POWER — Practice Guide on Obesity and Weight Management, Education, and Resources. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 631-649.e10.	4.4	112
147	A working paradigm for the treatment of obesity in gastrointestinal practice. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 52-60.	0.3	7
148	Bariatric surgery — time to replace with GLP-1?. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 635-640.	1.5	21
149	Vascular risk in obesity: Facts, misconceptions and the unknown. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 2-13.	2.0	26
150	Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. <i>BMC Obesity</i> , 2017, 4, 9.	3.1	10
151	Should bariatric surgery be performed in adolescents?. <i>European Journal of Endocrinology</i> , 2017, 176, D1-D15.	3.7	60
152	Acute Pancreatitis. <i>New England Journal of Medicine</i> , 2017, 376, 596-599.	27.0	52
153	Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. <i>Endocrine Connections</i> , 2017, 6, 89-99.	1.9	24
154	Practical Use of Pharmacotherapy for Obesity. <i>Gastroenterology</i> , 2017, 152, 1765-1779.	1.3	49
155	The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance. <i>Gastroenterology</i> , 2017, 152, 1707-1717.e2.	1.3	77
157	Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes. <i>Heart Lung and Circulation</i> , 2017, 26, 1133-1141.	0.4	10

#	ARTICLE	IF	CITATIONS
158	Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1555-1561.	4.4	23
159	Reversal of liver fibrosis: From fiction to reality. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 129-141.	2.4	128
160	A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorders. <i>Journal of Eating Disorders</i> , 2017, 5, 15.	2.7	47
161	The significance of beige and brown fat in humans. <i>Endocrine Connections</i> , 2017, 6, R70-R79.	1.9	63
162	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.	8.6	63
163	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2017, 5, CD012204.	2.8	31
164	Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity. <i>Endocrinología y Nutrición (English Ed)</i> , 2017, 64, 15-22.	0.2	16
165	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. <i>Diabetes Care</i> , 2017, 40, 839-848.	8.6	49
166	Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4293-4303.	6.4	89
167	Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters. <i>Drug Research</i> , 2017, 67, 318-326.	1.7	12
168	Effect of exenatide on postprandial glucose fluxes, lipolysis, and cell function in non-diabetic, morbidly obese patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 412-420.	4.4	15
169	Obesity. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17034.	30.5	766
170	Central administration of GLP-1 and GIP decreases feeding in mice. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 247-252.	2.1	73
171	Management of obesity in adult Asian Indians. <i>Indian Heart Journal</i> , 2017, 69, 539-544.	0.5	48
172	Epidemiology of Obesity and Pharmacologic Treatment Options. <i>Nutrition in Clinical Practice</i> , 2017, 32, 441-462.	2.4	21
173	Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?. <i>International Journal of Obesity</i> , 2017, 41, 1570-1578.	3.4	58
174	Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy. <i>Annals of Surgery</i> , 2017, 266, 82-90.	4.2	47
175	Current and cutting-edge interventions for the treatment of obese patients. <i>European Journal of Radiology</i> , 2017, 93, 134-142.	2.6	23

#	ARTICLE	IF	CITATIONS
176	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 719.	11.0	135
177	Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 447-456.	4.7	16
178	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. <i>Current Diabetes Reports</i> , 2017, 17, 34.	4.2	36
179	Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.. <i>Physiology and Behavior</i> , 2017, 177, 4-12.	2.1	10
180	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2364-2372.	3.6	72
181	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1529-1536.	4.4	52
182	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: <sc>S</sc>ustained reductions in body weight, glycaemia and blood pressure over 1â€%year. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1276-1288.	4.4	49
183	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm â€“ 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	2.1	362
184	Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2017, 40, 632-639.	8.6	84
185	Pharmacotherapy for Weight Management in the VHA. <i>Journal of General Internal Medicine</i> , 2017, 32, 70-73.	2.6	19
186	Novel antidiabetic medications for nonâ€alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2017, 47, 266-280.	3.4	53
187	Chrelin, CCK, GLP-1, and PYY(3â€“36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. <i>Physiological Reviews</i> , 2017, 97, 411-463.	28.8	414
188	7. Obesity Management for the Treatment of Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, S57-S63.	8.6	65
189	Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. <i>Journal of Pediatrics</i> , 2017, 181, 146-153.e3.	1.8	79
190	Liraglutide for weight management: benefits and risks. <i>Current Medical Research and Opinion</i> , 2017, 33, 537-539.	1.9	1
191	Hyperlipidemia-Induced MicroRNA-155-5p Improves Î²-Cell Function by Targeting<i>Mafk</i>. <i>Diabetes</i> , 2017, 66, 3072-3084.	0.6	41
192	Obesity and Brain Function. <i>Advances in Neurobiology</i> , 2017, , .	1.8	3
193	Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 890-899.	8.1	123

#	ARTICLE	IF	CITATIONS
194	Pasado, presente y futuro de la farmacoterapia para la obesidad. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 256-264.	0.8	3
195	Mechanisms responsible for homeostatic appetite control: theoretical advances and practical implications. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 401-415.	2.4	17
196	Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 303-313.	2.4	5
197	Roles of Gut Hormones in the Regulation of Food Intake and Body Weight. <i>Endocrinology</i> , 2017, , 1-14.	0.1	0
198	Current and emerging pharmacotherapies for obesity in Australia. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 501-521.	1.8	9
199	Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A <i>Post Hoc</i> Analysis. <i>Journal of Women's Health</i> , 2017, 26, 1161-1168.	3.3	7
200	Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. <i>Endocrine Development</i> , 2017, 32, 165-182.	1.3	12
201	Effects of Liraglutide on Weight Loss, Fat Distribution, and $\beta$ -Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1556-1564.	8.6	69
202	Central Modulation of Energy Homeostasis and Cognitive Performance After Bariatric Surgery. <i>Advances in Neurobiology</i> , 2017, 19, 213-236.	1.8	14
203	Efficacy and Safety of Cathine (Nor-Pseudoephedrine) in the Treatment of Obesity: A Randomized Dose-Finding Study. <i>Obesity Facts</i> , 2017, 10, 407-419.	3.4	24
204	Approaches to obesity management. <i>Internal Medicine Journal</i> , 2017, 47, 734-739.	0.8	16
205	Assessment of Weight Loss With the Intra-gastric Balloon in Patients With Different Degrees of Obesity. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, e83-e86.	0.8	11
207	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	2.3	6
208	Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 197-205.	0.8	79
209	Gut check on diabetes: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity. <i>Current Opinion in Pharmacology</i> , 2017, 37, 10-15.	3.5	11
210	Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G442-G447.	3.4	38
212	Past, present and future of pharmacotherapy for obesity. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2017, 29, 256-264.	0.2	4
213	Neural circuits of eating behaviour: Opportunities for therapeutic development. <i>Journal of Psychopharmacology</i> , 2017, 31, 1388-1402.	4.0	9

#	ARTICLE	IF	CITATIONS
214	Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m <sup>2</sup> : A Post-hoc Analysis. <i>Obesity Facts</i> , 2017, 10, 531-544.	3.4	27
215	Just a Gut Feeling: Central Nervous Effects of Peripheral Gastrointestinal Hormones. <i>Endocrine Development</i> , 2017, 32, 100-123.	1.3	6
216	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1081-1088.	2.6	21
217	Pharmacotherapy in the Management of Pediatric Obesity. <i>Current Diabetes Reports</i> , 2017, 17, 55.	4.2	14
219	Early-Onset Obesity Caused by Monogenic Disorders. <i>Current Pediatrics Reports</i> , 2017, 5, 100-110.	4.0	1
220	Lorcaserin plus lifestyle modification for weight loss maintenance: Rationale and design for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2017, 59, 105-112.	1.8	13
221	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0mg. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 44.	2.7	37
222	Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 2881-2891.	2.4	36
223	Liraglutide 3.0mg for weight management: weight-loss dependent and independent effects. <i>Current Medical Research and Opinion</i> , 2017, 33, 225-229.	1.9	27
224	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 211-223.	3.3	16
225	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 27-39.	2.4	30
226	Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 172-180.	4.4	36
227	Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016. <i>Endocrinología, Diabetes Y Nutrición</i> , 2017, 64, 15-22.	0.3	59
228	Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 409-415.	1.0	17
229	Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. <i>Techniques in Gastrointestinal Endoscopy</i> , 2017, 19, 12-17.	0.3	10
230	Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. <i>Obesity Reviews</i> , 2017, 18, 86-98.	6.5	56
231	Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. <i>Obesity Science and Practice</i> , 2017, 3, 425-433.	1.9	25
232	10. Medical and surgical management of obesity prior to planned pregnancy. , 2017, , 123-130.		0

#	ARTICLE	IF	CITATIONS
233	8. Konservative Therapie. , 2017, , 191-268.		0
235	Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. <i>Frontiers in Physiology</i> , 2017, 8, 294.	2.8	25
236	Obesity: A Review of Pathogenesis and Management Strategies in Adult. <i>Delta Medical College Journal</i> , 2017, 5, 35-48.	0.0	15
237	Tabaco y peso corporal. <i>Revista Chilena De Enfermedades Respiratorias</i> , 2017, 33, 249-251.	0.0	0
238	Weight loss medications in Canada &ndash;&nbsp;a new frontier or a repeat of past mistakes?. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 413-417.	2.4	9
239	Obesity Pharmacotherapy in Patients With Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2017, 30, 250-257.	1.0	29
240	GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity. , 2017, , 481-490.		1
241	The Management of Obesity. , 2017, , 47-57.		0
242	¼ Liraglutide for weight management. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 78-81.	0.3	1
243	Non-alcoholic Fatty Liver Disease: A Clinical Update. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, XX-XX.	1.4	98
244	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. <i>Nature Reviews Nephrology</i> , 2017, 13, 605-628.	9.6	233
245	Cardiometabolic Effects of Anti-obesity Pharmacotherapy. <i>Current Atherosclerosis Reports</i> , 2018, 20, 18.	4.8	7
246	Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13313.	3.0	37
247	Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats. <i>Journal of Psychopharmacology</i> , 2018, 32, 578-590.	4.0	28
248	Single Fluid-Filled Intra-gastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1073-1080.e1.	4.4	61
249	Glucagon-Like Peptide 1 and Human Obesity. , 2018, , 17-36.		1
250	Obesity and Polycystic Ovary Syndrome. , 2018, , 59-70.		0
251	Obesity and Cardiovascular Disease Prevention. , 2018, , 77-88.		1

#	ARTICLE	IF	CITATIONS
252	Medical Management of Patients Before and After Bariatric Surgery. , 2018, , 281-286.		0
253	A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 835-844.	2.1	8
254	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. <i>Clinical Obesity</i> , 2018, 8, 211-225.	2.0	10
255	Medically Supervised Weight Loss Programs. , 2018, , 211-223.		0
256	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 1-45.	0.1	3
257	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.5	86
258	Diabetes and Obesity. <i>Endocrinology</i> , 2018, , 1-49.	0.1	0
259	Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. <i>Neuropsychopharmacology</i> , 2018, 43, 2000-2008.	5.4	79
260	Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 238-248.	7.1	55
261	Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population*. <i>Military Medicine</i> , 2018, 183, 45-50.	0.8	3
262	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000475.	2.8	26
263	Safety and tolerability of new-generation anti-obesity medications: a narrative review. <i>Postgraduate Medicine</i> , 2018, 130, 173-182.	2.0	90
264	Prediabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 615-623.	1.7	72
265	Gut hormone polyagonists for the treatment of type 2 diabetes. <i>Peptides</i> , 2018, 100, 190-201.	2.4	96
266	Problem or solution: The strange story of glucagon. <i>Peptides</i> , 2018, 100, 36-41.	2.4	42
267	Pharmacotherapy for obesity in individuals with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 223-231.	1.8	15
268	Updates on obesity pharmacotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1411, 106-119.	3.8	65
269	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. <i>Heart Failure Reviews</i> , 2018, 23, 377-388.	3.9	16



#	ARTICLE	IF	CITATIONS
270	The safety of pharmacologic treatment for pediatric obesity. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 379-385.	2.4	32
271	Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. <i>ChemMedChem</i> , 2018, 13, 662-671.	3.2	62
272	Oxyntomodulin: Actions and role in diabetes. <i>Peptides</i> , 2018, 100, 48-53.	2.4	59
273	Newer GLP-1 receptor agonists and obesity-diabetes. <i>Peptides</i> , 2018, 100, 61-67.	2.4	54
274	Animal models of obesity and diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2018, 14, 140-162.	9.6	563
275	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	3.1	80
276	Incretins: Beyond type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 59-67.	4.4	8
277	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 22-33.	4.4	183
278	Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study. <i>Diabetes and Metabolism</i> , 2018, 44, 235-242.	2.9	19
279	New Therapies in Obesity. , 2018, , 271-279.		1
280	Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2018, 29, 246-253.	2.7	15
281	Obesity. <i>Journal of the American College of Cardiology</i> , 2018, 71, 69-84.	2.8	375
282	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1309-1319.e7.	1.3	56
283	Central Control of Energy Metabolism and Hypothalamic Obesity. <i>Contemporary Endocrinology</i> , 2018, , 27-42.	0.1	0
284	Gastrointestinal Hormones and the Control of Food Intake and Energy Metabolism. <i>Contemporary Endocrinology</i> , 2018, , 43-61.	0.1	0
285	Cardioprotective anti-hyperglycaemic medications: a review of clinical trials. <i>European Heart Journal</i> , 2018, 39, 2368-2375.	2.2	34
286	Glucagon-like peptide 1 in health and disease. <i>Nature Reviews Endocrinology</i> , 2018, 14, 390-403.	9.6	304
287	Prevention of Type 2 Diabetes. <i>Endocrinology</i> , 2018, , 1-20.	0.1	2



#	ARTICLE	IF	CITATIONS
288	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000464.	2.8	18
289	Practical Strategies for Engaging Individuals With Obesity in Primary Care. <i>Mayo Clinic Proceedings</i> , 2018, 93, 351-359.	3.0	36
290	Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. <i>Molecular Metabolism</i> , 2018, 11, 33-46.	6.5	66
291	The Science of Obesity Management: An Endocrine Society Scientific Statement. <i>Endocrine Reviews</i> , 2018, 39, 79-132.	20.1	522
292	Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. <i>Physiology and Behavior</i> , 2018, 192, 72-81.	2.1	30
293	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. <i>Advances in Therapy</i> , 2018, 35, 531-544.	2.9	12
294	Bimagrumb improves body composition and insulin sensitivity in insulin-resistant individuals. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 94-102.	4.4	59
295	Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. <i>Clinical Obesity</i> , 2018, 8, 1-10.	2.0	23
296	Brown rice compared to white rice slows gastric emptying in humans. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 367-373.	2.9	57
297	Pharmacotherapy for Patients with Obesity. <i>Clinical Chemistry</i> , 2018, 64, 118-129.	3.2	41
298	Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. <i>Obesity Reviews</i> , 2018, 19, 14-27.	6.5	39
299	Current pharmacotherapy for obesity. <i>Nature Reviews Endocrinology</i> , 2018, 14, 12-24.	9.6	287
300	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 610-619.	4.4	111
301	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 734-739.	4.4	71
302	Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option. <i>Journal of Investigative Medicine</i> , 2018, 66, 7-10.	1.6	49
303	Psychopharmacological advances in eating disorders. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 95-108.	3.1	84
304	Progress and challenges in anti-obesity pharmacotherapy. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 237-248.	11.4	210
305	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	3.4	144

#	ARTICLE	IF	CITATIONS
306	Addressing Obesity in Aging Patients. <i>Medical Clinics of North America</i> , 2018, 102, 65-85.	2.5	114
307	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. <i>Obesity</i> , 2018, 26, 70-80.	3.0	109
308	7. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2018. <i>Diabetes Care</i> , 2018, 41, S65-S72.	8.6	111
309	Obesity Pharmacotherapy. <i>Medical Clinics of North America</i> , 2018, 102, 135-148.	2.5	98
310	Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery. <i>Diabetes</i> , 2018, 67, 309-320.	0.6	42
311	Optimization of peptide-based polyagonists for treatment of diabetes and obesity. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2873-2881.	3.0	18
312	Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes. <i>American Journal of Lifestyle Medicine</i> , 2018, 12, 34-37.	1.9	3
313	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 13-24.	2.2	4
314	Is there an association between liraglutide use and female breast cancer in a real-world setting?. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 791-806.	2.4	9
315	Neuroendocrine Regulation of Appetite and Body Weight. , 2018, , 53-74.		0
316	Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome. , 2018, , .		1
319	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	1.5	17
320	The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE <sup>-/-</sup> and LDLR <sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways. <i>JACC Basic To Translational Science</i> , 2018, 3, 844-857.	4.1	224
321	Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	307
322	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1629-1647.	3.0	31
323	Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs. <i>Frontiers in Endocrinology</i> , 2018, 9, 719.	3.5	22
324	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 363, k4880.	2.3	33
325	Reprint of: Healthy Weight and Obesity Prevention. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3027-3052.	2.8	41

#	ARTICLE	IF	CITATIONS
326	A paradigm shift for the prevention and treatment of individual and global obesity. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 855-861.	2.4	4
327	Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop. <i>International Journal of Obesity</i> , 2018, 42, 1834-1844.	3.4	34
328	Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes for Both. <i>Endocrine Practice</i> , 2018, 24, 1093-1098.	2.1	1
329	Executive Summary of the 2018 Joint Consensus Document on Cardiovascular Disease Prevention in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 327-341.	2.2	18
330	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1856-1869.	2.8	68
331	Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome. <i>Current Opinion in Pharmacology</i> , 2018, 43, 118-123.	3.5	9
332	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	3.7	80
333	11th Annual Symposium on Self-Monitoring of Blood Glucose: April 12-14, 2018, Oslo, Norway. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 857-880.	4.4	0
334	Pediatric Obesity: Influence on Drug Dosing and Therapeutics. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S94-S107.	2.0	14
335	Diabetes and Obesity. <i>Endocrinology</i> , 2018, , 1-49.	0.1	3
336	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 571-615.	0.1	1
337	Clinical Practice Recommendations for the Management of Obesity in the United Arab Emirates. <i>Obesity Facts</i> , 2018, 11, 413-428.	3.4	13
338	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 683-697.	2.4	19
339	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e70-e87.	5.6	136
340	Healthy Weight and Obesity Prevention. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1506-1531.	2.8	306
341	Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1172.	7.4	308
342	Peptide-based multiagonists: a new paradigm in metabolic pharmacology. <i>Journal of Internal Medicine</i> , 2018, 284, 581-602.	6.0	40
343	Role of Cannabinoids in Obesity. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2690.	4.1	66

#	ARTICLE	IF	CITATIONS
344	Current and emerging pharmacotherapy for prediabetes: are we moving forward?. Expert Opinion on Pharmacotherapy, 2018, 19, 1663-1673.	1.8	7
345	Addressing Obesity in Clinical Gynecology Practice. Clinical Obstetrics and Gynecology, 2018, 61, 10-26.	1.1	5
346	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 606-624.	17.8	69
347	The Challenge of Obesity Treatment: A Review of Approved Drugs and New Therapeutic Targets. Journal of Epidemiology and Public Health Reviews, 2018, 04, .	0.1	5
348	Reducing the Risk of Developing Diabetes. Canadian Journal of Diabetes, 2018, 42, S20-S26.	0.8	18
349	Transient receptor potential (TRP) channels: a metabolic TR(i)P to obesity prevention and therapy. Obesity Reviews, 2018, 19, 1269-1292.	6.5	24
350	Weight Management in Diabetes. Canadian Journal of Diabetes, 2018, 42, S124-S129.	0.8	25
351	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. Current Atherosclerosis Reports, 2018, 20, 39.	4.8	20
352	How Ethical Is Our Current Delivery of Care to Patients with Severe and Complicated Obesity?. Obesity Surgery, 2018, 28, 2078-2082.	2.1	13
353	Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons. Diabetes, 2018, 67, 1538-1548.	0.6	84
354	The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2018, 142, 222-235.	2.8	18
355	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 2018, 28, 23-32.e3.	16.2	88
356	Obesity and Reproduction. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 950-966.	0.7	39
357	GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. Journal of Diabetes Research, 2018, 2018, 1-12.	2.3	76
358	Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?. Lancet, The, 2018, 391, 2577-2578.	13.7	6
359	No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century. Frontiers in Endocrinology, 2018, 9, 442.	3.5	22
360	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice, 2018, 24, 91-121.	2.1	388
361	Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs, 2018, 78, 1113-1132.	10.9	90

#	ARTICLE	IF	CITATIONS
362	Combination of Phentermine/Topiramate Er and Liraglutide 3 Mg for Intensive Therapy of Severe Obesity & T2Dm: A Case Series and Brief Review. <i>AACE Clinical Case Reports</i> , 2018, 4, e482-e486.	1.1	1
363	Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 3553-3558.	2.1	61
364	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 257-268.	4.7	12
365	Pharmacological Interventions for Obesity: Current and Future Targets. <i>Current Addiction Reports</i> , 2018, 5, 202-211.	3.4	11
366	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. <i>Cardiovascular Diabetology</i> , 2018, 17, 48.	6.8	33
368	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <scp>FIGHT</scp> trial. <i>ESC Heart Failure</i> , 2018, 5, 1035-1043.	3.1	25
369	Genetics of metabolic traits in Greenlanders: lessons from an isolated population. <i>Journal of Internal Medicine</i> , 2018, 284, 464-477.	6.0	10
370	Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 637-649.	13.7	446
371	Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. <i>Pharmacological Reviews</i> , 2018, 70, 712-746.	16.0	137
372	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2557-2564.	4.4	28
373	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <i>Hormones</i> , 2018, 17, 333-350.	1.9	43
374	Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 246-252.	3.1	79
375	Treatment: New Drugs. , 2019, , 464-472.		0
376	New Avenues in the Regulation of Gallbladder Motilityâ€”Implications for the Use of Glucagon-Like Peptideâ€”Derived Drugs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2463-2472.	3.6	16
377	Precision medicine in adult and pediatric obesity: a clinical perspective. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881986302.	3.2	30
378	Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a realâ€”world setting: The XENSOR Study. <i>International Journal of Clinical Practice</i> , 2019, 73, e13399.	1.7	46
379	Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.	8.6	35
380	Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1151-1159.	5.0	9

#	ARTICLE	IF	CITATIONS
381	Effectiveness of a Community-Based Weight Management Program for Patients Taking Antidepressants and/or Antipsychotics. <i>Obesity</i> , 2019, 27, 1539-1544.	3.0	1
382	Conversion from Prediabetes to Diabetes in Individuals with Obesity, 5-Years Post-Band, Sleeve, and Gastric Bypass Surgeries. <i>Obesity Surgery</i> , 2019, 29, 3901-3906.	2.1	1
383	Biopsychology of human appetite – understanding the excitatory and inhibitory mechanisms of homeostatic control. <i>Current Opinion in Physiology</i> , 2019, 12, 33-38.	1.8	6
384	Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study. <i>Clinical Obesity</i> , 2019, 9, e12329.	2.0	40
385	Efficacy and safety of liraglutide in Indian adolescents with obesity. <i>Obesity Science and Practice</i> , 2019, 5, 251-257.	1.9	10
386	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. <i>Korean Journal of Family Medicine</i> , 2019, 40, 63-71.	1.2	13
387	Obesity and Diabetes. , 2019, , 597-610.		0
388	Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109224.	5.6	17
389	Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. <i>Drugs</i> , 2019, 79, 1187-1197.	10.9	15
390	Adipose tissue as a key player in obstructive sleep apnoea. <i>European Respiratory Review</i> , 2019, 28, 190006.	7.1	69
391	Incretin Therapies: Current Use and Emerging Possibilities. , 2019, , 515-529.		0
392	Response to –Liraglutide Effectiveness: Is There a Real-World Clinical Benefit? <i>Obesity</i> , 2019, 27, 1728-1728.	3.0	0
393	Physiology of the Incretin Hormones, <sc>GIP</sc> and <sc>GLP</sc> – Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38
394	Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 219-224.	1.2	22
395	Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day. <i>Clinical Obesity</i> , 2019, 9, e12340.	2.0	6
396	Management of Diabetes in Patients Undergoing Bariatric Surgery. <i>Current Diabetes Reports</i> , 2019, 19, 112.	4.2	17
397	Personalized Management of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 115.	4.2	10
398	Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme. <i>Obesity Science and Practice</i> , 2019, 5, 468-478.	1.9	2

#	ARTICLE	IF	CITATIONS
399	Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway. <i>Cardiovascular Diabetology</i> , 2019, 18, 146.	6.8	42
400	Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00082.	2.4	8
401	Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?. <i>Obesity</i> , 2019, 27, 1727-1727.	3.0	0
402	Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery. <i>Obesity Surgery</i> , 2019, 29, 4095-4104.	2.1	23
403	Is pharmacotherapy enough for urgent weight loss in severely obese patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 367-371.	1.8	0
404	Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 349-357.	3.1	56
405	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. <i>Metabolism: Clinical and Experimental</i> , 2019, 100, 153960.	3.4	16
406	Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 468-484.	4.9	21
407	Cardiovascular risk and obesity. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 74.	2.7	236
408	Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. <i>Journal of the Endocrine Society</i> , 2019, 3, 1727-1747.	0.2	132
409	CD1 is involved in diet-induced hypothalamic inflammation in obesity. <i>Brain, Behavior, and Immunity</i> , 2019, 78, 78-90.	4.1	6
410	Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 679-690.	1.8	20
411	New Agents for the Treatment of Type 2 Diabetes. <i>Critical Care Clinics</i> , 2019, 35, 315-328.	2.6	13
412	Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies. <i>Clinical Obesity</i> , 2019, 9, e12294.	2.0	26
413	Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine. <i>Obesity</i> , 2019, 27, 288-294.	3.0	44
414	<p>Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 505-512.	2.4	14
415	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <i>Diabetes Care</i> , 2019, 42, 1446-1453.	8.6	84
416	Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 303-313.	1.3	4



#	ARTICLE	IF	CITATIONS
417	Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain postbariatric surgery. <i>Clinical Obesity</i> , 2019, 9, e12323.	2.0	83
418	Beinaglutide showed significant weight loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a realworld setting: a 3-month, multicentre, observational, retrospective, openlabel study. <i>Obesity Science and Practice</i> , 2019, 5, 366-375.	1.9	23
419	Current treatments for obesity. <i>Clinical Medicine</i> , 2019, 19, 205-212.	1.9	98
420	RealWorld Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. <i>Obesity</i> , 2019, 27, 917-924.	3.0	50
421	Patient Characteristics Associated with Receipt of Prescription WeightManagement Medications Among Veterans Participating in MOVE!. <i>Obesity</i> , 2019, 27, 1168-1176.	3.0	17
423	Issues in Measuring and Interpreting Human Appetite (Satiety/Satiation) and Its Contribution to Obesity. <i>Current Obesity Reports</i> , 2019, 8, 77-87.	8.4	91
424	Comorbidities of Obesity. , 2019, , 385-392.		0
425	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2019, 70, 1443-1456.	7.3	11
426	Peptone-mediated glucagonlike peptide-1 secretion depends on intestinal absorption and activation of basolaterally located CalciumSensing Receptors. <i>Physiological Reports</i> , 2019, 7, e14056.	1.7	36
427	Obesity and Fat Metabolism in Human Immunodeficiency VirusInfected Individuals: Immunopathogenic Mechanisms and Clinical Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 420-431.	4.0	64
428	Realworld prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1661-1667.	4.4	18
429	Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. <i>Journal of Cardiac Failure</i> , 2019, 25, 380-400.	1.7	122
430	Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. <i>British Journal of Surgery</i> , 2019, 106, 735-746.	0.3	16
431	Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT inhibitors and GLP-1 receptor agonists. <i>Journal of Internal Medicine</i> , 2019, 286, 16-31.	6.0	24
432	Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2019, 36, 1052-1074.	2.9	67
433	Safety and Effectiveness of LongerTerm Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. <i>Obesity</i> , 2019, 27, 591-602.	3.0	60
434	Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors. <i>Methods in Enzymology</i> , 2019, 622, 183-200.	1.0	10
435	Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1837-1848.	4.4	10



#	ARTICLE	IF	CITATIONS
436	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. <i>Obesity Reviews</i> , 2019, 20, 816-828.	6.5	139
437	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. <i>Drug Safety</i> , 2019, 42, 957-971.	3.2	22
438	From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 260.	3.5	71
439	Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, vi-xi.	3.4	6
440	Is reducing appetite beneficial for body weight management in the context of overweight and obesity? A systematic review and meta-analysis from clinical trials assessing body weight management after exposure to satiety enhancing and/or hunger reducing products. <i>Obesity Reviews</i> , 2019, 20, 983-997.	6.5	27
441	GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. <i>Neuropharmacology</i> , 2019, 151, 55-63.	4.1	15
442	Pharmacotherapy of Obesity: Limits and Perspectives. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 349-364.	2.2	14
443	Attenuation of satiety gut hormones increases appetitive behavior after curative esophagectomy for esophageal cancer. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 335-344.	4.7	9
444	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 941-949.	3.9	67
445	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 208-230.	0.7	147
446	Sustained behaviour change in healthy eating to improve obesity outcomes: It is time to abandon willpower to appreciate wanting. <i>Clinical Obesity</i> , 2019, 9, e12299.	2.0	11
447	Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880567.	3.2	6
448	Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight/obese adults. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1357-1364.	4.4	11
449	Microvascular and macrovascular effects of liraglutide. <i>International Journal of Cardiology</i> , 2019, 286, 17-18.	1.7	3
450	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019, 10, 155.	3.5	395
451	The Future Directions of Childhood Obesity and Clinical Management. , 2019, , 429-452.		1
452	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	2.1	245
453	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1498-1501.	4.4	61

#	ARTICLE	IF	CITATIONS
454	Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2019, 171, ITC65-ITC80.	3.9	46
455	Obesity. <i>Annals of Internal Medicine</i> , 2019, 170, ITC33.	3.9	36
456	The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. <i>African Health Sciences</i> , 2019, 19, 2591-2599.	0.7	21
457	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. <i>BMJ Open</i> , 2019, 9, e031431.	1.9	11
458	Current Treatments on Obesity. <i>Korean Journal of Health Promotion</i> , 2019, 19, 171.	0.2	2
459	Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1448-1451.	1.5	7
460	Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. <i>Scientific Reports</i> , 2019, 9, 19351.	3.3	43
461	An Approach to Obesity Management for Gastroenterologists and Hepatologists. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 587-601.	0.8	0
462	Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist. <i>Journal of Korean Diabetes</i> , 2019, 20, 149.	0.3	0
463	Moderate preventative effect with intraperitoneal liraglutide injection in high-fat diet induced C57BL/6J obese mouse model. <i>Obesity Medicine</i> , 2019, 16, 100153.	0.9	2
464	Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial. <i>Trials</i> , 2019, 20, 633.	1.6	15
465	GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2019, 18, 164.	6.8	15
466	Directive clinique No 391 - Grossesse et obésité maternelle Partie 1: Préconception et soins prénataux. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1641-1659.	0.7	0
467	Guideline No. 391-Pregnancy and Maternal Obesity Part 1: Pre-conception and Prenatal Care. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 1623-1640.	0.7	52
468	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 154.	4.2	6
469	The role of liraglutide in the management of obesity. <i>Journal of Aesthetic Nursing</i> , 2019, 8, 322-326.	0.1	0
470	Endocrine Mechanisms in Obesity. , 2019, , 79-85.		0
471	Gender-related issues in the pharmacology of new anti-obesity drugs. <i>Obesity Reviews</i> , 2019, 20, 375-384.	6.5	28

#	ARTICLE	IF	CITATIONS
473	Diabesity and antidiabetic drugs. <i>Molecular Aspects of Medicine</i> , 2019, 66, 3-12.	6.4	42
474	Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. <i>Nature Reviews Endocrinology</i> , 2019, 15, 90-104.	9.6	92
475	Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. <i>Obesity</i> , 2019, 27, 75-86.	3.0	63
476	Pharmacotherapy for Weight Management. , 2019, , 395-411.		4
477	Body Weight Considerations in the Management of Type 2 Diabetes. <i>Advances in Therapy</i> , 2019, 36, 44-58.	2.9	139
478	How do we identify people at high risk of Type 2 diabetes and help prevent the condition from developing?. <i>Diabetic Medicine</i> , 2019, 36, 316-325.	2.3	10
479	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12664.	2.6	29
480	Defined Paraventricular Hypothalamic Populations Exhibit Differential Responses to Food Contingent on Caloric State. <i>Cell Metabolism</i> , 2019, 29, 681-694.e5.	16.2	92
481	Precision Medicine in Weight Loss and Healthy Living. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 15-20.	3.1	31
482	Roles of Gut Hormones in the Regulation of Food Intake and Body Weight. <i>Endocrinology</i> , 2019, , 75-88.	0.1	0
483	Medications Indicated for Chronic Weight Management. <i>Endocrinology</i> , 2019, , 401-424.	0.1	0
484	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 585-593.	1.8	11
485	Pharmacologic Agents Chapter for Abdominal Obesity. , 2019, , 51-66.		1
486	Liraglutide effects in a paediatric (7-11Ây) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. <i>Pediatric Obesity</i> , 2019, 14, e12495.	2.8	45
487	The pathogenesis of obesity. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 26-36.	3.4	108
488	Statistics for Evaluating Pre-post Change: Relation Between Change in the Distribution Center and Change in the Individual Scores. <i>Frontiers in Psychology</i> , 2018, 9, 2696.	2.1	64
489	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 121-127.	1.2	13
490	New advances and novel approaches in obesity pharmacotherapy. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 4, 75-82.	1.4	1

#	ARTICLE	IF	CITATIONS
491	The role of gut hormones in obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 4, 4-13.	1.4	11
492	Pharmacotherapy of obesity: Available medications and drugs under investigation. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 170-192.	3.4	184
493	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 26-36.	4.5	30
494	Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1- $\beta$ cell signaling pathway. <i>Endocrine</i> , 2019, 64, 271-283.	2.3	37
496	Obesity and Therapeutic Approaches to Weight Loss. <i>Contemporary Cardiology</i> , 2019, , 71-85.	0.1	1
497	Choosing a Medication. , 2019, , 105-119.		0
498	Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 1-12.	2.4	45
499	The Regulation of Peripheral Metabolism by Gut-Derived Hormones. <i>Frontiers in Endocrinology</i> , 2018, 9, 754.	3.5	42
500	Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shorterterm vs. lifelong testosterone therapy. <i>Aging Male</i> , 2020, 23, 585-591.	1.9	5
501	Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2020, 44, 93-102.	0.8	35
502	Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 141-159.	2.4	49
503	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 104-126.	3.8	57
504	Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost. <i>Diabetology International</i> , 2020, 11, 49-56.	1.4	0
505	Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features. <i>Cancer Reports</i> , 2020, 3, e1211.	1.4	23
506	Intensification of medical management in type 2 diabetes: A real-world look at primary care practice. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107477.	2.3	3
507	One Month Weight Loss Predicts the Efficacy of Liraglutide in Obese Patients: Data from A Single Center. <i>Endocrine Practice</i> , 2020, 26, 235-240.	2.1	8
508	Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 35-44.	1.5	4
509	Pharmacological antagonism of the incretin system protects against diet-induced obesity. <i>Molecular Metabolism</i> , 2020, 32, 44-55.	6.5	37

#	ARTICLE	IF	CITATIONS
510	An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy, 2020, 21, 275-285.	1.8	34
511	Advances in oral peptide therapeutics. Nature Reviews Drug Discovery, 2020, 19, 277-289.	46.4	354
512	Anorectic state of obesity medications in the United States. Are leaner times ahead?. Expert Opinion on Pharmacotherapy, 2020, 21, 167-172.	1.8	4
513	Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 2-10.	2.3	21
514	The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obesity Science and Practice, 2020, 6, 162-170.	1.9	26
515	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Review of Clinical Pharmacology, 2020, 13, 53-64.	3.1	79
516	Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Research, 2020, 1727, 146562.	2.2	23
517	Obesity medications in development. Expert Opinion on Investigational Drugs, 2020, 29, 63-71.	4.1	30
518	Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. Neuroscience, 2020, 447, 191-215.	2.3	11
519	COVID-19 and obesity: an opportunity for change. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882094974.	3.2	4
521	Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. Current Opinion in Pharmacology, 2020, 53, 101-116.	3.5	10
522	SEEDO-SEMERGEN consensus document on continuous care of obesity between primary care and specialist Hospital units 2019. Medicina Clínica (English Edition), 2020, 155, 267.e1-267.e11.	0.2	6
523	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism: Clinical and Experimental, 2020, 111, 154343.	3.4	36
524	Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach. Diabetes, Obesity and Metabolism, 2020, 22, 969-977.	4.4	5
525	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology and Metabolic Syndrome, 2020, 12, 60.	2.7	321
526	Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients. Journal of Diabetes Investigation, 2020, 11, 1524-1531.	2.4	11
527	Bariatric Embolization. Advances in Clinical Radiology, 2020, 2, 101-112.	0.2	0
528	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	2.7	137

#	ARTICLE	IF	CITATIONS
529	Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. <i>Obesity Science and Practice</i> , 2020, 6, 439-444.	1.9	17
531	Obesity and Related Type 2 Diabetes: A Failure of the Autonomic Nervous System Controlling Gastrointestinal Function?. <i>Gastrointestinal Disorders</i> , 2020, 2, 423-447.	0.8	0
532	Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD013516.	2.8	9
533	Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension. <i>Annals of Internal Medicine</i> , 2020, 173, 685-693.	3.9	55
534	The risk of cardiovascular complications with current obesity drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1095-1104.	2.4	14
535	Liraglutide for Weight Reduction in Obese Adolescents. <i>AAP Grand Rounds</i> , 2020, 44, 19-20.	0.0	0
536	Harnessing cyclotides to design and develop novel peptide GPCR ligands. <i>RSC Chemical Biology</i> , 2020, 1, 177-191.	4.1	18
537	Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like Tj ETQq1 1 0.784314 rgBT /Overlock with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apneaâ€“hypnoea index (AHI). <i>BMI Open</i> . 2020. 10. e038856.	1.9	9
538	Blood Pressure-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	1
539	A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization. <i>Digestive Disease Interventions</i> , 2020, 04, 195-205.	0.2	0
540	Obesity in adults: a clinical practice guideline. <i>Cmaj</i> , 2020, 192, E875-E891.	2.0	592
541	Slower Growth Exists Before Celiac Disease Diagnosis. <i>AAP Grand Rounds</i> , 2020, 44, 20-20.	0.0	0
544	Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a crossâ€“sectional study in a tertiary nephrology centre. <i>Clinical Obesity</i> , 2020, 10, e12402.	2.0	17
545	Weight loss: Lifestyle interventions andÂpharmacotherapy. , 2020, , 219-234.		1
546	Testosterone Therapy for Prevention and Treatment of Obesity in Men. <i>Androgens: Clinical Research and Therapeutics</i> , 2020, 1, 40-61.	0.5	8
547	Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. <i>Current Obesity Reports</i> , 2020, 9, 391-401.	8.4	9
548	Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. <i>Diabetes Therapy</i> , 2020, 11, 2221-2235.	2.5	14
549	A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 1863-1872.	1.9	5

#	ARTICLE	IF	CITATIONS
550	Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation. <i>Neurourology and Urodynamics</i> , 2020, 39, 1922-1929.	1.5	4
551	Overview of bariatric and metabolic endoscopy interventions. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , 2020, 13, 263177452093523.	1.9	7
552	Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. <i>JGH Open</i> , 2020, 4, 995-1001.	1.6	7
553	Medical Weight Loss Outcomes in Patients Receiving Concomitant Psychotropic Medication: A Retrospective Cohort Study. <i>Obesity</i> , 2020, 28, 1671-1677.	3.0	3
555	Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient. <i>ACG Case Reports Journal</i> , 2020, 7, e00380.	0.4	3
556	Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice. <i>Heliyon</i> , 2020, 6, e05190.	3.2	1
557	Actualizaci3n cl3nica de la obesidad y el sobrepeso. <i>Medicine</i> , 2020, 13, 777-786.	0.0	0
558	Weight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions. <i>Current Obesity Reports</i> , 2020, 9, 412-423.	8.4	13
560	Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. <i>Obesity Science and Practice</i> , 2020, 6, 382-389.	1.9	4
561	Recent Updates on Obesity Treatments: Available Drugs and Future Directions. <i>Neuroscience</i> , 2020, 437, 215-239.	2.3	46
562	Regression from prediabetes to normal glucose regulation: State of the science. <i>Experimental Biology and Medicine</i> , 2020, 245, 889-896.	2.4	29
563	Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome. <i>Current Diabetes Reports</i> , 2020, 20, 26.	4.2	17
564	The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. <i>Current Obesity Reports</i> , 2020, 9, 136-149.	8.4	18
565	Meta-analysis of cardiovascular superiority trials published in the <i>New England Journal of Medicine</i> to elucidate the concept of superiority margin. <i>Postgraduate Medical Journal</i> , 2021, 97, 227-233.	1.8	0
566	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	3.9	8
567	The effects of supplementation with L-arginine on anthropometric indices and body composition in overweight or obese subjects: A systematic review and meta-analysis. <i>Journal of Functional Foods</i> , 2020, 71, 104022.	3.4	6
569	Obesity Treatment. <i>Orthopaedic Nursing</i> , 2020, 39, 121-127.	0.4	3
570	Medications Available for Weight Reduction in Elective Total Joint Arthroplasty. <i>JBJS Reviews</i> , 2020, 8, e0123-e0123.	2.0	4



#	ARTICLE	IF	CITATIONS
571	Visceral fat metabolic activity evaluated by 18F-FDG PET/CT is associated with osteoporosis in healthy postmenopausal Korean women. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 339-344.	1.8	7
572	No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1837-1846.	4.4	4
573	GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis. <i>Obesity Surgery</i> , 2020, 30, 3561-3569.	2.1	7
574	Medications for the treatment of obesity in adolescents. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882091878.	3.2	24
575	HIV and antiretroviral therapy-related fat alterations. <i>Nature Reviews Disease Primers</i> , 2020, 6, 48.	30.5	104
576	Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. <i>BioMed Research International</i> , 2020, 2020, 1-10.	1.9	14
577	Probiotic Mixture of <i>Lactobacillus plantarum</i> Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice. <i>Frontiers in Microbiology</i> , 2020, 11, 512.	3.5	95
578	Long-Term Evaluation of a UK Community Pharmacy-Based Weight Management Service. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 22.	1.6	4
579	Leveraging the Gut to Treat Metabolic Disease. <i>Cell Metabolism</i> , 2020, 31, 679-698.	16.2	53
580	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1328-1338.	4.4	26
581	New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice. <i>Bioconjugate Chemistry</i> , 2020, 31, 1167-1176.	3.6	21
582	A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. <i>New England Journal of Medicine</i> , 2020, 382, 2117-2128.	27.0	288
583	Ferritin-Displayed GLP-1 with Improved Pharmacological Activities and Pharmacokinetics. <i>Molecular Pharmaceutics</i> , 2020, 17, 1663-1673.	4.6	7
585	Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies. <i>Molecules</i> , 2020, 25, 1093.	3.8	8
586	Extrinsic compression of pancreatic duct by intragastric balloon treatment and its potential to cause acute pancreatitis: two case reports and clinical discussion. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 191-193.	1.8	1
587	Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high-fat diet. <i>Animal Models and Experimental Medicine</i> , 2020, 3, 62-68.	3.3	4
588	Resistant Hypertension in a Dialysis Patient. <i>Hypertension</i> , 2020, 76, 278-287.	2.7	1
589	Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1779-1785.	3.3	16



#	ARTICLE	IF	CITATIONS
590	Mobile Apps for Weight Management: A Review of the Latest Evidence to Inform Practice. <i>Frontiers in Endocrinology</i> , 2020, 11, 412.	3.5	67
591	Pharmacological therapies to address obesity in type 1 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 194-206.	2.3	7
592	Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes. <i>Epidemiology</i> , 2020, 31, 559-566.	2.7	3
593	The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. <i>Current Obesity Reports</i> , 2020, 9, 255-271.	8.4	39
594	Reproductive Consequences of Obesity. , 2020, , .		1
595	Extrinsic compression of pancreatic duct by intragastric balloon treatment and its potential to cause acute pancreatitis: Two case reports and clinical discussion. <i>Obesity Research and Clinical Practice</i> , 2020, 14, 290-292.	1.8	3
596	Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist. <i>Journal of Controlled Release</i> , 2020, 325, 111-120.	9.9	8
597	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1064-e1074.	3.6	42
598	Modern pharmacological treatment of obese patients. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201881989752.	3.2	55
599	Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. <i>Obesity</i> , 2020, 28, 529-536.	3.0	85
600	Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 171-192.	1.6	64
601	Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX). <i>Journal of Psychiatric Research</i> , 2020, 124, 9-12.	3.1	8
602	Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108087.	2.8	15
603	Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. <i>International Journal of Obesity</i> , 2020, 44, 1254-1263.	3.4	54
604	Cardiovascular Risks and Benefits of Medications Used for Weight Loss. <i>Frontiers in Endocrinology</i> , 2019, 10, 883.	3.5	12
605	Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154167.	3.4	23
606	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946.	4.4	126
607	Pharmacological Treatment for Obesity in Adults: An Umbrella Review. <i>Annals of Pharmacotherapy</i> , 2020, 54, 691-705.	1.9	28

#	ARTICLE	IF	CITATIONS
608	The Societal Value of Broader Access to Antiobesity Medications. <i>Obesity</i> , 2020, 28, 429-436.	3.0	13
609	Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP-1 Receptor Agonists. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1956-1974.	2.8	48
610	Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. <i>Atherosclerosis</i> , 2020, 300, 10-18.	0.8	6
611	Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide. <i>Physiology and Behavior</i> , 2020, 220, 112870.	2.1	4
612	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	2.1	410
613	Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. <i>PLoS ONE</i> , 2020, 15, e0231196.	2.5	23
614	Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approaches. <i>European Respiratory Journal</i> , 2020, 56, 1902295.	6.7	37
615	Appetite, the enteroendocrine system, gastrointestinal disease and obesity. <i>Proceedings of the Nutrition Society</i> , 2021, 80, 50-58.	1.0	18
616	Pharmacological Management of Obese Patients with Type 2 Diabetes amid COVID-19 Pandemic. <i>Obesity Surgery</i> , 2021, 31, 413-414.	2.1	2
617	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers. <i>Postgraduate Medicine</i> , 2021, 133, 310-319.	2.0	8
618	Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study. <i>Obesity Surgery</i> , 2021, 31, 93-100.	2.1	30
619	Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study. <i>Obesity Surgery</i> , 2021, 31, 84-92.	2.1	24
620	A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 363-373.	4.4	31
621	GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.	6.5	518
622	Albumin-binding domain extends half-life of glucagon-like peptide-1. <i>European Journal of Pharmacology</i> , 2021, 890, 173650.	3.5	17
623	Endoscopic sleeve gastropasty plus liraglutide versus endoscopic sleeve gastropasty alone for weight loss. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1316-1324.e1.	1.0	27
624	Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. <i>Hepatology</i> , 2021, 73, 2051-2062.	7.3	10
625	Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 291-302.	0.8	9

#	ARTICLE	IF	CITATIONS
626	The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions – Effectiveness, tolerability and impact on eating behaviours: A 52-week observational study. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 49-57.	1.8	6
627	Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 912-921.	3.6	27
628	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 754-762.	4.4	134
629	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. <i>Nature Reviews Cardiology</i> , 2021, 18, 291-304.	13.7	141
630	The long-term risk of cardiovascular events in patients following bariatric surgery compared to a non-surgical population with obesity and the general population: a comprehensive national cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 189-196.	1.9	11
631	Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon – a Case-Matched Study. <i>Obesity Surgery</i> , 2021, 31, 1204-1213.	2.1	14
632	Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 50-62.	4.4	53
633	Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 271-281.	2.2	4
634	Cardiovascular outcome trials in obesity: A review. <i>Obesity Reviews</i> , 2021, 22, e13112.	6.5	41
635	Childhood and Adolescent Obesity: A Review. <i>Frontiers in Pediatrics</i> , 2020, 8, 581461.	1.9	166
636	Targeting Enteroendocrine Cells to Treat Metabolic Disease. , 2021, , .		1
637	Clinical effectiveness of liraglutide on weight loss in South Koreans. <i>Medicine (United States)</i> , 2021, 100, e23780.	1.0	13
638	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , 2020, 11, 617400.	3.5	25
639	Pharmacologie de l'obésité : vers de nouvelles options. , 2021, , 663-672.		0
640	Economic value of nonsurgical weight loss in adults with obesity. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 37-50.	0.9	11
641	<sc>Glucagon-like</sc> peptide-1 receptor agonists in the era of <sc>COVID</sc>-19: Friend or foe?. <i>Clinical Obesity</i> , 2021, 11, e12439.	2.0	21
642	Obesity: Medical and Surgical Treatment. , 2021, , 131-175.		0
643	Long-term effects of weight-reducing drugs in people with hypertension. <i>The Cochrane Library</i> , 2021, 1, CD007654.	2.8	10

#	ARTICLE	IF	CITATIONS
644	Adolescent Obesity. , 2021, , .		0
645	Liraglutide for overweight and obesity. Practical Diabetes, 2021, 38, 7.	0.3	2
647	Pharmacologic Weight Loss: An Underutilized Practice in the Fight Against Obesity. Interventions in Obesity & Diabetes, 2021, 4, .	0.0	0
648	Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy. Inquiry (United States), 2021, 58, 004695802199051.	0.9	3
649	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. American Journal of Clinical Nutrition, 2021, 113, 314-323.	4.7	24
650	Prevention and Treatment of Obesity for Cardiovascular Risk Mitigation: Dietary and Pharmacologic Approaches. Contemporary Cardiology, 2021, , 129-141.	0.1	0
651	Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World Journal of Men?s Health, 2021, 39, 208.	3.3	71
653	Management of Obesity in Adults with CKD. Journal of the American Society of Nephrology: JASN, 2021, 32, 777-790.	6.1	49
654	Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015â€”2018. Obesity Surgery, 2021, 31, 2391-2400.	2.1	28
655	MedikamentÃ¶se Therapie der Adipositas. Ã„rztliche Psychotherapie, 2021, 16, 16-21.	0.1	0
656	Role of SGLT2 inhibitors in the treatment of visceral obesity. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2648.	1.4	0
657	Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. European Journal of Medicinal Chemistry, 2021, 212, 113118.	5.5	11
658	Binge-Eating Disorder and Type 2 Diabetes: A Review. Endocrine Practice, 2021, 27, 158-164.	2.1	20
659	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open, 2021, 11, e044711.	1.9	3
660	Glucagon-Like Peptide-1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type-2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy, 2021, 12, 969-989.	2.5	9
661	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18, 5-99.	1.2	49
662	Long-Term Weight Loss Strategies for Obesity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1854-1866.	3.6	32
663	Obesity as a <sc>multisystem</sc> disease: Trends in obesity rates and <sc>obesityâ€™related</sc> complications. Diabetes, Obesity and Metabolism, 2021, 23, 3-16.	4.4	133

#	ARTICLE	IF	CITATIONS
664	Liraglutide to Improve coronary haemodynamics during Exercise stress (LIONESS): a double-blind randomised placebo-controlled crossover trial. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 17.	2.7	2
666	An update on pharmacotherapeutic strategies for obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1305-1318.	1.8	6
667	The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1262-1271.	4.4	28
668	Current and future therapies for type 1 diabetes. <i>Diabetologia</i> , 2021, 64, 1037-1048.	6.3	65
670	BINGE EATING DISORDERS; UPDATED AND EMERGING APPROACHES. <i>International Journal of Applied Pharmaceutics</i> , 0, , 84-93.	0.3	0
671	Clinical Impact of Liraglutide as a Treatment of Obesity. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 53-60.	1.2	21
672	Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 618208.	3.5	5
673	GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. <i>Molecular Metabolism</i> , 2021, 45, 101163.	6.5	19
674	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021, 384, 989-1002.	27.0	1,374
675	Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <i>Lancet</i> , 2021, 397, 971-984.	13.7	429
677	A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine. <i>Scientific Reports</i> , 2021, 11, 7583.	3.3	13
678	GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk. <i>European Heart Journal</i> , 2021, 42, 1652-1653.	2.2	5
680	GLP-1 and Intestinal Diseases. <i>Biomedicines</i> , 2021, 9, 383.	3.2	20
681	Promising areas of pharmacotherapy for obesity. <i>Russian Journal of Cardiology</i> , 2021, 26, 4279.	1.4	3
682	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1414.	7.4	413
683	Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?. <i>Drugs</i> , 2021, 81, 881-893.	10.9	9
684	Practical Approaches to Treating Obesity: Patient and Healthcare Professional Perspectives. <i>Advances in Therapy</i> , 2021, 38, 4138-4150.	2.9	2
685	Understanding the appetite modulation pathways: The role of the FFA1 and FFA4 receptors. <i>Biochemical Pharmacology</i> , 2021, 186, 114503.	4.4	5

#	ARTICLE	IF	CITATIONS
686	Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2103-2113.	3.6	6
687	Prediabetes and What It Means: The Epidemiological Evidence. <i>Annual Review of Public Health</i> , 2021, 42, 59-77.	17.4	116
688	Obesity Primer for the Practicing Gastroenterologist. <i>American Journal of Gastroenterology</i> , 2021, 116, 918-934.	0.4	6
689	Proglucagon-Derived Peptides as Therapeutics. <i>Frontiers in Endocrinology</i> , 2021, 12, 689678.	3.5	34
690	Approach to Obesity in the Older Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2788-2805.	3.6	7
691	Effect of liraglutide 3.0 mg on eating behavior in patients with obesity. <i>Meditinskiy Sovet</i> , 2021, , 156-164.	0.5	2
692	Role of enteroendocrine hormones in appetite and glycemia. <i>Obesity Medicine</i> , 2021, 23, 100332.	0.9	7
693	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide-1 Receptor Agonists. <i>Advances in Therapy</i> , 2021, 38, 2821-2839.	2.9	70
695	Pharmacotherapy for weight loss in adults with type 2 diabetes: a systematic review of randomised controlled trials. <i>British Journal of Diabetes</i> , 2021, 21, 20-29.	0.2	1
696	How do you treat obesity in the elderly pharmacologically?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1639-1642.	1.8	0
697	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1013-1025.	5.7	6
698	Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. <i>Pediatric Obesity</i> , 2021, 16, e12799.	2.8	6
699	Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients. <i>Psychiatry Research</i> , 2021, 299, 113830.	3.3	10
700	Advances in Application of Azobenzene as a Trigger in Biomedicine: Molecular Design and Spontaneous Assembly. <i>Advanced Materials</i> , 2021, 33, e2007290.	21.0	118
701	Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population. , 2021, 38, 220-226.		1
702	Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E874-E885.	3.5	25
703	Obesity and responsibility: Is it time to rethink agency?. <i>Obesity Reviews</i> , 2021, 22, e13270.	6.5	16
704	Obesity in Renal Transplantation. <i>Nephron</i> , 2021, 145, 614-623.	1.8	3

#	ARTICLE	IF	CITATIONS
705	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	27.0	171
706	Association of metabolic bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 participants. <i>Lancet, The</i> , 2021, 397, 1830-1841.	13.7	241
707	Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664. <i>British Journal of Diabetes</i> , 2021, 21, 120-122.	0.2	1
708	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.8	9
709	Early onset of acute pancreatitis in a patient on low-dose liraglutide. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 753-755.	3.6	2
710	Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review. <i>Advances in Nutrition</i> , 2021, 12, 2540-2552.	6.4	10
711	Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist. <i>Journal of Korean Diabetes</i> , 2021, 22, 126-133.	0.3	3
712	Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. <i>Endocrinology and Metabolism</i> , 2021, 36, 647-660.	3.0	17
713	Semaglutide for Weight Loss. <i>Annals of Pharmacotherapy</i> , 2022, 56, 224-226.	1.9	2
714	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss. <i>European Heart Journal</i> , 2021, 42, 2628-2629.	2.2	0
715	Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2777-2791.	2.8	49
716	Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021120.	3.7	10
717	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	3.1	8
718	The Anti-Obesity Effect of Traditional Chinese Medicine on Lipid Metabolism. <i>Frontiers in Pharmacology</i> , 2021, 12, 696603.	3.5	15
719	Obesity and GLP-1. <i>Minerva Endocrinology</i> , 2021, 46, 168-176.	1.1	14
720	A 2021 Update on the Use of Liraglutide in the Modern Treatment of "Diabetes": A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 669.	2.0	14
721	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. <i>Frontiers in Endocrinology</i> , 2021, 12, 694284.	3.5	22
722	Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity. <i>Frontiers in Endocrinology</i> , 2021, 12, 687918.	3.5	1



#	ARTICLE	IF	CITATIONS
723	Eficacia y seguridad de liraglutida para la disminución de peso en adultos: revisión sistemática. Revista Colombiana De Endocrinología, Diabetes & Metabolismo, 2021, 7, 250-257.	0.0	1
724	Clinical management and treatment of obesity in China. Lancet Diabetes and Endocrinology, the, 2021, 9, 393-405.	11.4	105
726	Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2807-2827.	2.4	32
727	Effects of <sc>glucagon-like</sc> peptide-1 analogue treatment in genetic obesity: A case series. Clinical Obesity, 2021, 11, e12481.	2.0	11
728	Un largo y pedregoso camino hacia el correcto tratamiento de la obesidad. Medicina Clínica, 2021, 157, 176-177.	0.6	0
729	Experts'™ opinion on the detection and management of prediabetes in Lebanon. Science Progress, 2021, 104, 003685042110294.	1.9	0
730	A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's™ Perspective. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 3147-3160.	2.4	2
731	Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery. Current Treatment Options in Gastroenterology, 2021, 19, 524-541.	0.8	5
732	Pharmacotherapy in Childhood Obesity. Hormone Research in Paediatrics, 2022, 95, 177-192.	1.8	9
733	Cardiovascular Safety and Superiority of Anti-Obesity Medications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 3199-3208.	2.4	7
734	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. Journal of Women's Health, 2021, 30, 1016-1027.	3.3	5
735	Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. Seminars in Liver Disease, 2021, 41, 435-447.	3.6	12
736	Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). Diabetes Therapy, 2021, 12, 2133-2147.	2.5	20
737	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opinion on Emerging Drugs, 2021, 26, 231-243.	2.4	51
738	Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity. JAMA Network Open, 2021, 4, e2116595.	5.9	13
739	Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1171-1188.	5.7	17
740	Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 385, e4.	27.0	24
741	Safety of Semaglutide. Frontiers in Endocrinology, 2021, 12, 645563.	3.5	66

#	ARTICLE	IF	CITATIONS
742	Pharmacotherapy of obesity: An update. <i>Pharmacological Research</i> , 2021, 169, 105649.	7.1	28
743	Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein. <i>Annals of Translational Medicine</i> , 2021, 9, 1157-1157.	1.7	0
744	Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 39-48.	2.5	5
745	Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 694476.	3.5	5
746	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <i>Lancet, The</i> , 2021, 398, 262-276.	13.7	222
747	Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. <i>Trials</i> , 2021, 22, 464.	1.6	4
748	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1193-1204.	3.1	12
749	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3257-3270.	2.6	7
750	Diets and drugs for weight loss and health in obesity – An update. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111789.	5.6	68
751	Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. <i>British Journal of Pharmacology</i> , 2022, 179, 557-570.	5.4	46
752	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 669-672.	27.0	0
753	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 29-38.	3.6	82
754	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2587-2595.	2.6	7
755	Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. <i>Obesity Facts</i> , 2021, 14, 568-576.	3.4	15
756	The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1440-1448.	1.2	0
758	A long and stony road to the correct treatment of obesity. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 176-177.	0.2	0
759	Antiobesity drug therapy: An individualized and comprehensive approach. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 440-448.	1.3	9
760	Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. <i>Nutrients</i> , 2021, 13, 2830.	4.1	27

#	ARTICLE	IF	CITATIONS
761	Obesity Management in Cardiometabolic Disease: State of the Art. <i>Current Atherosclerosis Reports</i> , 2021, 23, 59.	4.8	16
762	Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 60.	4.8	3
763	Gut microbiota: a target for intervention in obesity. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1169-1179.	3.0	11
764	Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E392-E409.	3.5	12
765	Gastrointestinal peptides in eating-related disorders. <i>Physiology and Behavior</i> , 2021, 238, 113456.	2.1	9
768	Obesity – An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. <i>Biomolecules</i> , 2021, 11, 1426.	4.0	35
769	Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity. <i>Frontiers in Endocrinology</i> , 2021, 12, 735019.	3.5	39
770	Dynamin regulates L cell secretion in human gut. <i>Molecular and Cellular Endocrinology</i> , 2021, 535, 111398.	3.2	5
771	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 747-756.	2.2	2
772	Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression. <i>Diabetes Research and Clinical Practice</i> , 2021, 179, 109031.	2.8	41
773	Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121043.	5.2	6
774	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021, 3, 100322.	4.9	109
775	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 94-105.	4.4	34
776	Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice. <i>Canadian Journal of Diabetes</i> , 2022, 46, 216-224.e2.	0.8	7
777	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18522.	3.3	21
778	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 595-605.	11.4	61
779	A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing. <i>Molecular Metabolism</i> , 2021, 53, 101240.	6.5	41
780	Obesity and cancer. Two sides of the same problem. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 95.	0.6	2

#	ARTICLE	IF	CITATIONS
781	Intermittent fasting for the prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD013496.	2.8	34
782	Binge-Related Eating Disorders (Binge Eating Disorder and Bulimia Nervosa). , 2021, , 35-53.		0
783	A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects. Frontiers in Pharmacology, 2020, 11, 610880.	3.5	5
784	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. International Journal of Obesity, 2021, 45, 923-933.	3.4	28
785	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Current Obesity Reports, 2021, 10, 14-30.	8.4	136
786	Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. International Journal of Obesity, 2021, 45, 776-786.	3.4	19
787	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity, 2020, 28, 1050-1061.	3.0	148
788	Insulin Resistance and Other Mechanisms of Obesity Hypertension. , 2017, , 1-22.		1
789	Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Structure and Function, 2021, 226, 225-245.	2.3	20
790	Obesity therapy. Clinical Nutrition ESPEN, 2020, 38, 9-18.	1.2	17
791	Effects of incretin therapy and bariatric surgery on inflammation in obese patients. Obesity Medicine, 2019, 13, 13-20.	0.9	5
792	Surgical and Nonsurgical Weight Loss for Patients with Obstructive Sleep Apnea. Otolaryngologic Clinics of North America, 2020, 53, 409-420.	1.1	9
794	Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies. Techniques and Innovations in Gastrointestinal Endoscopy, 2020, 22, 154-158.	0.9	5
795	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 2020, 1, 100006.	6.5	22
796	Is reduction in appetite beneficial for body weight management in the context of overweight and obesity? Yes, according to the SATIN (Satiety Innovation) study. Journal of Nutritional Science, 2019, 8, e39.	1.9	18
797	Obesity and Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, S44-S51.	1.2	5
798	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 104-111.	3.0	23
799	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open, 2020, 10, e034137.	1.9	5

#	ARTICLE	IF	CITATIONS
800	Treatment of Obesity in Mitigating Metabolic Risk. <i>Circulation Research</i> , 2020, 126, 1646-1665.	4.5	36
801	Discovery, characterization, and clinical development of the glucagon-like peptides. <i>Journal of Clinical Investigation</i> , 2017, 127, 4217-4227.	8.2	253
802	Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2695-e2709.	3.6	140
803	Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity. <i>Obesity and Metabolism</i> , 2018, 15, 3-11.	1.2	7
805	Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care. <i>British Journal of Diabetes</i> , 2016, 16, 128.	0.2	5
806	Effects of liraglutide on obesity-associated functional hypogonadism in men. <i>Endocrine Connections</i> , 2019, 8, 195-202.	1.9	43
807	Strategies and methods for the correction of obesity and associated cardiovascular risk. <i>Russian Journal of Cardiology</i> , 2019, , 61-67.	1.4	8
808	Latest Developments and Future Perspectives in the Field Of Obesity. <i>European Endocrinology</i> , 2017, 13, 17.	1.5	4
809	A review on the current drugs and new targets for obesity. <i>Journal of Applied Pharmaceutical Research</i> , 2020, 8, 11-21.	0.2	3
810	Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. <i>Annals of Translational Medicine</i> , 2018, 6, 131-131.	1.7	18
811	Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?. <i>Annals of Translational Medicine</i> , 2018, 6, 186-186.	1.7	3
812	Liraglutide for the Treatment of Obesity: Analyzing Published Reviews. <i>Current Pharmaceutical Design</i> , 2019, 25, 1783-1790.	1.9	5
813	Current Options for the Pharmacotherapy of Obesity. <i>Current Pharmaceutical Design</i> , 2019, 25, 2019-2032.	1.9	5
814	Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence. <i>Current Diabetes Reviews</i> , 2020, 16, 699-715.	1.3	8
815	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. <i>Current Hypertension Reviews</i> , 2021, 17, 94-111.	0.9	9
816	Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1232-1243.	1.2	13
817	A Fully Automated Conversational Artificial Intelligence for Weight Loss: Longitudinal Observational Study Among Overweight and Obese Adults. <i>JMIR Diabetes</i> , 2017, 2, e28.	1.9	113
818	Electronic Quality of Life Assessment Using Computer-Adaptive Testing. <i>Journal of Medical Internet Research</i> , 2016, 18, e240.	4.3	48

#	ARTICLE	IF	CITATIONS
819	Review of Associations Between Type 2 Diabetes and Cancer. <i>Clinical Diabetes</i> , 2020, 38, 256-265.	2.2	11
820	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. <i>Minerva Endocrinologica</i> , 2020, 45, 127-137.	1.8	24
822	In Vivo Models for Incretin Research: From the Intestine to the Whole Body. <i>Endocrinology and Metabolism</i> , 2016, 31, 45.	3.0	5
823	Optimizing diabetes treatment in the presence of obesity. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, S22-S29.	1.3	12
824	Pharmacotherapy for obesity: What you need to know. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 951-958.	1.3	28
825	Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 248.	4.7	7
826	Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 802-818.	4.7	65
827	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. <i>World Journal of Diabetes</i> , 2019, 10, 291-303.	3.5	14
828	ÂNASH: A glance at the landscape of pharmacological treatment. <i>Annals of Hepatology</i> , 2016, 15, 673-81.	1.5	23
829	The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. <i>Journal of Obesity and Metabolic Syndrome</i> , 2019, 28, 158-166.	3.6	16
830	Current Long-Term Pharmacotherapies for the Management of Obesity. <i>Journal of Obesity and Metabolic Syndrome</i> , 2020, 29, 99-109.	3.6	13
831	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. <i>The Korean Journal of Obesity</i> , 2016, 25, 121-128.	0.2	2
832	Effectiveness, tolerability and practical application of the newer generation anti-obesity medications. <i>Drugs in Context</i> , 2016, 5, 1-7.	2.2	11
833	Obesity-Related Glomerulopathy: Clinical Management. <i>Seminars in Nephrology</i> , 2021, 41, 358-370.	1.6	6
836	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768119.	2.4	24
837	GLP-1 physiology informs the pharmacotherapy of obesity. <i>Molecular Metabolism</i> , 2022, 57, 101351.	6.5	119
838	Understanding the pathophysiologic pathways that underlie obesity and options for treatment. <i>Expert Review of Endocrinology and Metabolism</i> , 2021, 16, 321-338.	2.4	8
839	Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. <i>Endocrine Reviews</i> , 2022, 43, 507-557.	20.1	39

#	ARTICLE	IF	CITATIONS
840	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	2.8	28
841	Treating the Chronic Disease of Obesity. Medical Clinics of North America, 2021, 105, 983-1016.	2.5	15
842	The Endocrine Regulation of Energy and Body Weight. Endocrinology, 2016, , 1-22.	0.1	0
843	Liraglutide (Saxenda&lt;sup&gt;&#174;&lt;/sup&gt;) as a Treatment for Obesity. Food and Nutrition Sciences (Print), 2016, 07, 227-235.	0.4	3
844	Anti-obesity and Anti-fatty Liver Effects of Cynara scolymus L. Leaf Extract in Mice under Diet-induced Obesity. International Journal of Biochemistry Research & Review, 2016, 11, 1-11.	0.1	5
845	New Drugs for Obesity Treatment. Korean Journal of Medicine, 2016, 90, 121-126.	0.3	1
846	Advances in Pharmacological Treatment of Pediatric Obesity. , 2016, , 333-351.		0
847	Individualizing Lifestyle Therapy for Patients with Obesity. Endocrine Practice, 2016, 22, 14-20.	2.1	0
848	Obesity, Spermatogenesis, and Male Infertility. , 2017, , 167-182.		1
849	Ischemic Stroke and Homonymous Visual Field Defects. , 2017, , 31-41.		0
850	Medications Indicated for Chronic Weight Management. Endocrinology, 2017, , 1-24.	0.1	0
852	Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes and Obesity, 2017, 4, 1-6.	0.2	0
853	Pharmacotherapy for Weight Loss. , 2017, , 277-296.		0
854	Pharmacotherapy for Weight Loss. , 2017, , 277-296.		0
855	Weight Loss Medication in Bariatric Surgery. Journal of Metabolic and Bariatric Surgery, 2017, 6, 1-5.	0.6	0
856	Liraglutid bei Adipositas. Pharma-Kritik (discontinued), 2017, 39, .	0.0	0
857	The place of central-acting drugs in the algorithms of treatment of primary obesity. Obesity and Metabolism, 2017, 14, 18-23.	1.2	2
859	Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities. Contemporary Endocrinology, 2018, , 613-627.	0.1	1



#	ARTICLE	IF	CITATIONS
860	Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia. <i>European Journal of Case Reports in Internal Medicine</i> , 2017, 2, 000712.	0.4	1
861	Liraglutide: another reason to target prediabetes?. <i>Oncotarget</i> , 2017, 8, 99203-99204.	1.8	1
862	Obesity and Metabolic Syndrome Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 705-722.	0.1	3
863	The Endocrine Regulation of Energy and Body Weight. <i>Endocrinology</i> , 2018, , 589-610.	0.1	0
864	Insulin Resistance and Other Mechanisms of Obesity Hypertension. , 2018, , 91-112.		0
865	Fall 40: Therapie â€“ 60 Jahre, â™™, PrÃdiabetes, metabolisches Syndrom, Ãbergewicht. , 2018, , 157-159.		0
866	Enfoque terapÃ©utico de la diabetes mellitus tipo 2 en adultos. MÃs allÃ de una meta glucÃmica. <i>Medicina UPB</i> , 2018, 37, 36-46.	0.1	1
867	Prevention of Type 2 Diabetes. <i>Endocrinology</i> , 2018, , 465-484.	0.1	0
869	Recent Advances in Anti-Obesity Agents. <i>Korean Journal of Medicine</i> , 2018, 93, 501-508.	0.3	10
870	Short-term monotherapy with Liraglutide for weight management: A case study. <i>Journal of Family Medicine and Primary Care</i> , 2019, 8, 1804.	0.9	2
871	Diabetes and Obesity. <i>Endocrinology</i> , 2019, , 1-49.	0.1	0
873	GLP-1 analogue liraglutide as adjunct treatment in diabetes type 2 after failed bariatric/metabolic surgery. <i>Annals of Translational Medicine</i> , 2019, 7, S240-S240.	1.7	4
875	Intentos para perder peso en una poblaciÃn con sobrepeso y obesidad referida a un centro de endocrinologÃa en Colombia. <i>Medunab</i> , 2019, 22, 314-321.	0.1	0
876	Eficacia y seguridad de la liraglutida como tratamiento coadyuvante para disminuir el Ãndice de masa corporal. <i>Revista Salud Bosque</i> , 2020, 9, .	0.0	0
877	Male health and obesity â€“ diagnostic and therapeutic approach. <i>Obesity and Metabolism</i> , 2019, 16, 29-36.	1.2	7
878	Simple Obesity Treatment by Single Intervention of Herbal Medicines without Ephedra Herba: A Case Report. <i>The Journal of Internal Korean Medicine</i> , 2019, 40, 1294-1302.	0.3	1
879	Morbid Obesity. , 2020, , 23-29.		1
880	Diabetes and Obesity. <i>Endocrinology</i> , 2020, , 1-49.	0.1	1

#	ARTICLE	IF	CITATIONS
881	Treatment of Type 2 Diabetes in Subjects with Obesity: What is the Best Approach?. Interventions in Obesity & Diabetes, 2020, 4, .	0.0	0
883	Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. World Chinese Journal of Digestology, 2020, 28, 393-400.	0.1	0
885	Gastrointestinal Hormones in Healthy Adults: Reliability of Repeated Assessments and Interrelations with Eating Habits and Physical Activity. Nutrients, 2021, 13, 3809.	4.1	1
886	Perirenal Adipose Tissue from Healthy Donor: Characteristics and Promise as Potential Therapeutic Cell Source. Journal of Clinical Medicine, 2021, 10, 5024.	2.4	5
887	Cardiorenal outcomes in eligible patients referred for bariatric surgery. Obesity, 2021, 29, 2035-2043.	3.0	4
890	Obesity Management and Prevention of Cardiovascular Disease. Contemporary Cardiology, 2021, , 119-148.	0.1	0
891	Therapeutic Management of Obesity. Contemporary Cardiology, 2021, , 323-339.	0.1	1
892	Obesity and schizophrenia: New drugs, new hopes. Psihijatrija Danas, 2020, 52, 113-130.	0.1	0
893	Weight, shape, and body composition changes at menopause. Journal of Mid-Life Health, 2021, 12, 187.	0.6	10
894	Nutritional Follow-Up During Intra-gastric Balloon Treatment. , 2020, , 229-237.		0
895	Pharmacological Options for NASH. , 2020, , 309-327.		0
896	Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery. , 2021, , 1-15.		0
897	Long-Term Current Management of Enduring Obesity in Diabetes. Journal of Korean Diabetes, 2020, 21, 21-26.	0.3	0
898	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. Journal of Diabetes Research, 2021, 2021, 1-17.	2.3	1
899	Human Brown Adipose Tissue and Metabolic Health: Potential for Therapeutic Avenues. Cells, 2021, 10, 3030.	4.1	32
900	The Impact of a Clinical Pharmacist in an Interdisciplinary Weight Loss Service: A Follow-Up Study. Innovations in Pharmacy, 2021, 12, 13.	0.6	0
901	Symbiosis of cardiology and endocrinology. Meditsinskiy Sovet, 2020, , 80-89.	0.5	2
903	Glucagon-like peptide-1 receptor agonist reduces di(2-ethylhexyl) phthalate-induced atherosclerotic processes in vascular smooth muscle cells. Physiological Research, 2020, 69, 1095-1102.	0.9	5

#	ARTICLE	IF	CITATIONS
904	No evidence for benefit of medication for obesity. Canadian Family Physician, 2017, 63, 276.	0.4	0
905	Should family physicians prescribe medication for obesity? YES. Canadian Family Physician, 2017, 63, 102-103.	0.4	5
906	Should family physicians prescribe medication for obesity? NO. Canadian Family Physician, 2017, 63, 103-105.	0.4	3
908	Les mÃ©decins de famille devraient-ils prescrire des mÃ©dicaments contre l'obÃ©sité? NON. Canadian Family Physician, 2017, 63, 108-109.	0.4	0
909	Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 6-16.	0.6	1
910	Diet and exercise in the management of PCOS: Starting from the basics. , 2022, , 97-115.		0
911	Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus. JPGN Reports, 2021, 2, e141.	0.4	1
912	Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Molecular Metabolism, 2022, 55, 101407.	6.5	24
914	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. International Journal of Obesity, 2022, 46, 555-563.	3.4	16
915	Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved. Obesity Facts, 2022, 15, 83-89.	3.4	18
916	Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women. Frontiers in Endocrinology, 2021, 12, 742873.	3.5	11
917	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, The, 2021, 398, 2160-2172.	13.7	74
918	Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery, 2022, 21, 201-223.	46.4	357
920	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 2022, 134, 14-19.	2.0	46
921	Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study. Obesity Science and Practice, 2022, 8, 320-327.	1.9	10
922	Comparison of Beinsaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 358-367.	1.2	7
923	Obesity in cystic fibrosis. Journal of Clinical and Translational Endocrinology, 2021, 26, 100276.	1.4	13
924	Antiobesity drug therapy. Cleveland Clinic Journal of Medicine, 2021, 88, 657.1-657.	1.3	0

#	ARTICLE	IF	CITATIONS
925	Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis. <i>EClinicalMedicine</i> , 2021, 42, 101213.	7.1	41
926	Research Progress of Liraglutide in Improving Obesity. <i>Advances in Clinical Medicine</i> , 2021, 11, 5501-5506.	0.0	0
927	Predictive Modeling for Decision Support in the Tasks of Selecting the Drug for Obesity Treatment. <i>Procedia Computer Science</i> , 2021, 193, 371-381.	2.0	1
929	Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. <i>Endocrine</i> , 2022, 75, 718-724.	2.3	26
930	Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 138.	7.4	293
931	Drug Therapy of Childhood Obesity. <i>Journal of Nutrition &amp; Food Sciences</i> , 2018, 08, .	1.0	0
932	Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis. <i>Cardiology Journal</i> , 2020, , .	1.2	1
933	Drugs for Treating Obesity. <i>Handbook of Experimental Pharmacology</i> , 2021, , 387-414.	1.8	12
934	Glucagon-Like Peptide-1 Receptor Agonistsâ€™ Use in Clinical Practice. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 328-336.	1.4	5
935	Dietary and Medical Management of Obesity. , 2022, , 1826-1832.		0
936	SÃndrome metabÃlico: revisiÃn de la literatura. <i>Medicina Y Laboratorio</i> , 2022, 26, 47-62.	0.1	4
937	Liraglutide Activates Type 2 Deiodinase and Enhances $\beta$ 3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue. <i>Frontiers in Endocrinology</i> , 2021, 12, 803363.	3.5	6
938	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12028.	1.7	8
939	Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 155-163.	2.4	9
940	Is polypharmacy the future for pharmacological management of obesity?. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022, 23, 100322.	1.4	5
941	Medical Management of Obesity as it Affects Reflux. <i>Foregut</i> , 0, , 263451612110691.	0.5	1
942	Highlights of mechanisms and treatment of obesity-related hypertension. <i>Journal of Human Hypertension</i> , 2022, 36, 785-793.	2.2	13
943	Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes. <i>Obesity Surgery</i> , 2022, 32, 1005-1015.	2.1	16

#	ARTICLE	IF	CITATIONS
944	GLP-1RAs for the treatment of obesity in women after menopause. <i>Maturitas</i> , 2022, 156, 65-66.	2.4	1
945	Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 193-206.	11.4	90
946	Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia. <i>Lancet Diabetes and Endocrinology</i> , 2022, , .	11.4	0
947	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 281-295.	2.4	35
948	New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1339-e1347.	3.6	33
949	Etiopathogenesis of Obesity. , 2021, , 1-12.		0
951	Research Progress of Slimming Products and Their Pharmacological Mechanisms. <i>Hans Journal of Food and Nutrition Science</i> , 2022, 11, 73-79.	0.1	0
953	Efecto de liraglutide sobre los niveles de andr3genos s3ricos y la funci3n sexual en mujeres con obesidad. <i>Revista Colombiana De EndocrinologAa, Diabetes &amp; Metabolismo</i> , 2021, 8, .	0.0	0
955	Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2022, Volume 17, 405-414.	2.3	10
956	Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. <i>Diabetes Therapy</i> , 2022, 13, 453-464.	2.5	13
957	Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review. <i>Frontiers in Nutrition</i> , 2022, 9, 804719.	3.7	15
958	Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta-analysis of randomized control trials. <i>Obesity Reviews</i> , 2022, 23, e13435.	6.5	53
959	Obesity — A Matter of Motivation?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 290-295.	1.2	1
960	Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 819470.	3.5	4
961	Integrating High-Dose GLP-1 Receptor Agonists Into the Care of People With or at Risk for Type 2 Diabetes. <i>ADCES in Practice</i> , 0, , 2633559X2210862.	0.2	0
962	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 359-375.	2.0	22
964	Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 838410.	3.5	42
965	Implementation of Cardiometabolic Centers and Training Programs. <i>Current Diabetes Reports</i> , 2022, , 1.	4.2	0

#	ARTICLE	IF	CITATIONS
966	Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 165-180.	4.7	10
967	Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?. <i>JAMA Internal Medicine</i> , 2022, 182, 520.	5.1	2
968	Meta-analysis: analysis of mechanistic pathways in the treatment of <sc>non-alcoholic</sc> steatohepatitis. Evidence from a Bayesian network <sc>meta-analysis</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1076-1087.	3.7	15
969	Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 944-959.	3.7	17
971	Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review. <i>Obesity Reviews</i> , 2022, 23, e13448.	6.5	42
972	Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3451.	4.1	14
973	Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia. <i>Cureus</i> , 2022, 14, e23554.	0.5	0
976	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	2.4	9
977	The Impact of Obesity on Sudden Cardiac Death Risk. <i>Current Cardiology Reports</i> , 2022, 24, 497-504.	2.9	7
978	Pancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis. <i>Current Opinion in Pharmacology</i> , 2022, 63, 102199.	3.5	8
979	Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1676-1680.	4.4	7
980	How the COVID-19 pandemic has affected obesity levels and how liraglutide may play a role in its control. <i>Journal of Aesthetic Nursing</i> , 2022, 11, 118-126.	0.1	1
981	Novel drugs in pharmacotherapy of obesity. <i>Prakticki Lekarski Vestnik</i> , 2021, 17, 74-80.	0.1	0
982	A contemporary view on obesity treatment in adults. <i>Reproductive Endocrinology</i> , 2021, , 45-50.	0.3	3
983	Typ-2-Diabetes: Gewichtsreduktion per stufenweiser Eskalation. , 0, , .		0
984	The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8643-8650.	1.8	2
985	Obesity, Inflammation, and Severe Asthma: an Update. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 46.	5.3	29
986	Semaglutide for the treatment of obesity. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 159-166.	4.9	26

#	ARTICLE	IF	CITATIONS
987	Adding liraglutide to diet and exercise to maintain weight loss “ is it worth it?. Expert Opinion on Pharmacotherapy, 2022, 23, 447-451.	1.8	0
988	Pharmacotherapy of obesity in complex diseases. Clinical Obesity, 2022, 12, e12497.	2.0	6
989	High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination. Clinics and Practice, 2022, 12, 1-7.	1.4	2
990	The Effects of Freshwater Clam ( <i>Corbicula fluminea</i> ) Extract on Serum Tumor Necrosis Factor-Alpha (TNF- $\alpha$ ) in Prediabetic Patients in Taiwan. Marine Drugs, 2022, 20, 261.	4.6	3
991	Regulation of feeding and therapeutic application of bioactive peptides. , 2022, 239, 108187.		4
992	The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults. Frontiers in Nutrition, 2022, 9, 818263.	3.7	11
993	Semaglutide: a game changer for metabolic diseases?. Exploration of Medicine, 0, , 173-180.	1.5	1
994	Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. , 2022, 2, 100018.		13
995	Japanese traditional Kampo medicine bofutsushosan improves body mass index in participants with obesity: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0266917.	2.5	4
996	Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study. , 2022, 2, 100016.		2
1000	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Review of Clinical Pharmacology, 2022, , 1-17.	3.1	5
1002	Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical Obesity. SSRN Electronic Journal, 0, , .	0.4	0
1003	Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 8503-8508.	2.4	2
1004	The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research, 2022, 54, 458-471.	1.5	12
1005	Slow and steady wins the race: 25 years developing the GLP-1 receptor as an effective target for weight loss. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	4
1006	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy, 2022, 39, 2452-2467.	2.9	58
1007	Letter of reply to the letter by Ryan. Diabetes, Obesity and Metabolism, 2022, 24, 1682-1685.	4.4	0
1008	Methodological issues with meta-analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1681-1681.	4.4	1



#	ARTICLE	IF	CITATIONS
1009	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends in Endocrinology and Metabolism, 2022, 33, 424-442.	7.1	23
1010	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiologica, 2023, 78, 552-564.	0.9	2
1011	Multiagonists of the "incretin axis" as a promising tool for managing cardiometabolic risk in visceral obesity. Russian Journal of Cardiology, 2022, 27, 4755.	1.4	0
1012	Obesity, weight loss and gynecologic neoplasms: a narrative review. Women and Health, 0, , 1-12.	1.0	0
1013	Type 2 Diabetes Remission with Significant Weight Loss: Definition and Evidence-Based Interventions. Journal of Obesity and Metabolic Syndrome, 2022, 31, 123-133.	3.6	4
1014	Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Current Atherosclerosis Reports, 2022, 24, 643-654.	4.8	13
1016	An Overview of Treatment Modalities and Management Aspects for Obesity. Current Nutrition and Food Science, 2023, 19, 105-113.	0.6	4
1017	Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. Circulation, 2022, 145, 1642-1644.	1.6	2
1018	Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2022, 11, 2998.	2.4	10
1019	Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity " A proof of concept study. Clinical Nutrition ESPEN, 2022, 50, 238-246.	1.2	2
1021	The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients, 2022, 14, 2217.	4.1	8
1023	Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022, 387, 205-216.	27.0	799
1024	GLP-1 analogues in clinical management of obesity. Current Opinion in Endocrine and Metabolic Research, 2022, , 100360.	1.4	3
1025	Multiagonists of the "incretin axis" as a promising tool for managing cardiometabolic risk in visceral obesity. Russian Journal of Cardiology, 2022, 27, 4755.	1.4	1
1026	Obesity-related vascular dysfunction persists after weight loss and is associated with decreased vascular glucagon-like peptide receptor in female rats. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H301-H311.	3.2	2
1027	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 2022, 45, 2396-2405.	8.6	19
1028	Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.9	0
1030	Medical Weight Management: A Multidisciplinary Approach. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1031	Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. <i>Fertility and Sterility</i> , 2022, 118, 371-381.	1.0	28
1032	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232211080.	2.5	10
1033	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. , 2022, 18, 43.		4
1034	Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?. , 2022, 18, 35.		5
1035	Efficacy of liraglutide 3.0mg treatment on weight loss in patients with weight regain after bariatric surgery. <i>Eating and Weight Disorders</i> , 2022, 27, 2775-2781.	2.5	17
1037	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <i>Endocrinology and Metabolism</i> , 2022, 37, 415-429.	3.0	3
1038	Appetite Control Mechanisms and Obesity. <i>Journal of Korean Diabetes</i> , 2022, 23, 89-96.	0.3	0
1039	Recent Advances in Anti-Obesity Drugs. <i>Journal of Korean Diabetes</i> , 2022, 23, 113-127.	0.3	2
1040	Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities. <i>Pharmaceutics</i> , 2022, 14, 1445.	4.5	9
1041	<scp>INnoVative</scp> trial design for testing the Efficacy, Safety, and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 <scp>DIAbetes</scp> in autoantibody positive participants: a protocol for three parallel double-blind randomised controlled trials () Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 37	2.3	2
1042	Beyond diet and exercise: another option for patients with obesity and polycystic ovary syndrome?. <i>Fertility and Sterility</i> , 2022, , .	1.0	0
1043	Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	19
1044	Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 7495-7501.	0.8	1
1045	Obesity pillars roundtable: Phentermine – Past, present, and future. , 2022, 3, 100024.		5
1046	A narrative review of anti-obesity medications for obese patients with osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1381-1395.	1.8	4
1047	Anti-obesity weight loss medications: Short-term and long-term use. <i>Life Sciences</i> , 2022, 306, 120825.	4.3	5
1048	The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2022, 13, 204201882211124.	3.2	9
1049	Pharmacologic treatment of obesity. <i>Journal of the Korean Medical Association</i> , 2022, 65, 408-416.	0.3	0

#	ARTICLE	IF	CITATIONS
1050	Efficacy and Safety of Liraglutide 3.0mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-14.	1.7	10
1051	Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial. <i>Obesity</i> , 2022, 30, 1608-1620.	3.0	34
1052	Acts of appetite: neural circuits governing the appetitive, consummatory, and terminating phases of feeding. <i>Nature Metabolism</i> , 2022, 4, 836-847.	11.9	32
1053	The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. <i>Discover Oncology</i> , 2022, 13, .	2.1	0
1054	Pharmacotherapy in obesity: the current state and the near future. <i>Journal of the Korean Medical Association</i> , 2022, 65, 514-531.	0.3	0
1056	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€”2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	2.1	146
1057	Outcomes of Endoscopic Sleeve Gastroplasty in the Elder Population. <i>Obesity Surgery</i> , 2022, 32, 3390-3397.	2.1	5
1058	Derivatization with fatty acids in peptide and protein drug discovery. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 59-80.	46.4	19
1059	Medical and Surgical Treatment of Obesity. <i>Medical Clinics of North America</i> , 2022, 106, 837-852.	2.5	3
1060	Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108286.	2.3	1
1061	The role of GLP-1 receptor agonists in managing type 2 diabetes. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 457-464.	1.3	8
1062	Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. <i>Annals of Hepatology</i> , 2023, 28, 100751.	1.5	2
1063	Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-3.	3.1	0
1064	Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study. <i>Farmakoekonomika</i> , 2022, 15, 320-331.	1.2	2
1065	Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting. <i>Journal of Obesity and Metabolic Syndrome</i> , 2022, 31, 254-262.	3.6	2
1066	Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease. <i>Atherosclerosis</i> , 2022, 359, 1-12.	0.8	8
1067	Medical Management of Obesity. , 2021, , 1-19.		0
1068	Suboptimal Weight Loss After Bariatric Surgery: Mechanisms and Treatment Algorithms. , 2022, , 1-14.		0

#	ARTICLE	IF	CITATIONS
1070	The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. <i>Obesity Research and Clinical Practice</i> , 2022, 16, 353-363.	1.8	14
1071	GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?. <i>Current Atherosclerosis Reports</i> , 2022, 24, 867-884.	4.8	23
1072	Signaling pathways in obesity: mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	72
1073	Are Current Guidelines Perpetuating Weight Stigma? A Weight-Skeptical Approach to the Care of Patients with Obesity. <i>Journal of General Internal Medicine</i> , 0, , .	2.6	1
1074	Impact of refitted $\text{race}^{\text{free}}$ eGFR formula on obesity pharmacotherapy options. <i>Obesity</i> , 2022, 30, 2204-2212.	3.0	2
1075	Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
1076	A new era in gut hormone-based pharmacotherapy for people with obesity. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 217-226.	1.0	5
1077	Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
1078	Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	4
1079	NAFLD and thyroid function: pathophysiological and therapeutic considerations. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 755-768.	7.1	14
1081	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	15
1082	Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	3
1084	New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 522-528.	2.6	7
1085	Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. <i>Obesity Medicine</i> , 2022, 35, 100456.	0.9	8
1086	Obesity and diabetes in people of African ancestry with HIV. <i>HIV Medicine</i> , 2023, 24, 380-388.	2.2	2
1087	Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 108, 4-12.	3.6	11
1088	Factors associated with successful weight loss after liraglutide treatment for obesity. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 377-386.	4.4	5
1089	Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1461-1469.	3.1	6

#	ARTICLE	IF	CITATIONS
1090	Evaluation of a pharmacist's impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting. <i>Family Practice</i> , 2023, 40, 255-260.	1.9	1
1091	Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: <sc>STEP</sc> 1 and 4 exploratory analyses. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 468-478.	4.4	23
1092	Recognition of Obesity and Perceptions of Weight Loss Management in Patients With Chronic Kidney Disease: A Retrospective Cross-Sectional Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812211294.	1.1	2
1094	Obesity in Adults: A 2022 Adapted Clinical Practice Guideline for Ireland. <i>Obesity Facts</i> , 2022, 15, 736-752.	3.4	13
1098	Tirzepatide Once Weekly for the Treatment of Obesity. <i>New England Journal of Medicine</i> , 2022, 387, 1433-1435.	27.0	5
1099	Semaglutide for the treatment of overweight and obesity: A review. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 18-35.	4.4	26
1100	Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs). , 2022, 4, 100039.		6
1103	GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. <i>Microorganisms</i> , 2022, 10, 2061.	3.6	14
1104	The effects and side effects of liraglutide as a treatment for obesity. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2022, 4, 142-148.	0.1	0
1105	GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	15
1107	Type 2 diabetes. <i>Lancet, The</i> , 2022, 400, 1803-1820.	13.7	176
1108	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. <i>Gastroenterology</i> , 2022, 163, 1198-1225.	1.3	39
1109	Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. <i>Primary Care Diabetes</i> , 2022, , .	1.8	0
1110	Management of non-alcoholic fatty liver disease patients with sleep apnea syndrome. <i>World Journal of Gastroenterology</i> , 0, 28, 6099-6108.	3.3	0
1111	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. <i>Obesity Facts</i> , 2023, 16, 149-163.	3.4	4
1112	Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice. <i>Journal of Biological Chemistry</i> , 2022, 298, 102682.	3.4	5
1113	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-9.	2.5	9
1114	Liraglutide versus colesevelam for treating bile acid diarrhoea – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1075-1076.	8.1	0

#	ARTICLE	IF	CITATIONS
1115	Liraglutide versus colesevelam for treating bile acid diarrhoea. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1075.	8.1	0
1116	Brown adipose tissue and regulation of human body weight. <i>Diabetes/Metabolism Research and Reviews</i> , 2023, 39, .	4.0	8
1117	Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, , .	3.2	1
1118	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Diseaseâ€”Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842211463.	2.0	15
1119	Approach to the Patient With Hypothalamic Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1236-1242.	3.6	4
1120	Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. <i>Cell Reports</i> , 2022, 41, 111698.	6.4	8
1121	Liraglutide as an innovative and multifunctional drug for patients with obesity â€” the current state of knowledge and future prospects. <i>Journal of Education, Health and Sport</i> , 2022, 13, 153-160.	0.1	0
1122	New therapies for obesity. <i>Cardiovascular Research</i> , 2024, 119, 2825-2842.	3.8	16
1123	Investigating the potential nonâ€”authorized use of two different formulations of liraglutide in Europe: A realâ€”world drug utilization study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 985-991.	4.4	0
1124	Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. <i>Nature Reviews Endocrinology</i> , 2023, 19, 201-216.	9.6	44
1125	Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. <i>Clinical Epidemiology</i> , 0, Volume 14, 1463-1476.	3.0	10
1126	Tirzepatide for the treatment of obesity: Rationale and design of the <sc>SURMOUNT</sc> clinical development program. <i>Obesity</i> , 2023, 31, 96-110.	3.0	22
1127	Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. <i>Sleep and Breathing</i> , 2023, 27, 1687-1694.	1.7	5
1128	Therapeutics in Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 255-273.	1.6	0
1129	Marked weight loss on liraglutide 3.0Âµg: Realâ€”life experience of a <sc>S</sc>wiss cohort with obesity. <i>Obesity</i> , 2023, 31, 74-82.	3.0	7
1130	Obesity in South and Southeast Asiaâ€”A new consensus on care and management. <i>Obesity Reviews</i> , 2023, 24, .	6.5	22
1131	Fat â€” pharmacological therapies. <i>British Journal of Diabetes</i> , 2022, 22, S59-S61.	0.2	0
1132	A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center. , 2022, 4, 100046.		4

#	ARTICLE	IF	CITATIONS
1133	Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.. <i>Experimental and Clinical Psychopharmacology</i> , 2023, 31, 612-620.	1.8	1
1134	Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment. <i>World Journal of Diabetes</i> , 0, 13, 1096-1105.	3.5	2
1136	Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting. <i>Family Practice</i> , 2023, 40, 629-637.	1.9	2
1137	Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 15, 3961-3987.	2.4	5
1138	Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes. <i>Presse Medicale</i> , 2023, 52, 104160.	1.9	1
1139	The "breakthrough" obesity drugs that have stunned researchers. <i>Nature</i> , 2023, 613, 16-18.	27.8	6
1140	Obesity and diabetes: the final frontier. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 81-94.	2.4	4
1142	An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal. <i>Journal of the Endocrine Society</i> , 2023, 7, .	0.2	5
1144	GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1703.	4.1	31
1145	Effect of tirzepatide on prediabetics and blood pressure with implications for future research. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2023, 34, 243-244.	1.3	0
1146	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2023, 43, 1-7.	2.1	3
1147	Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. <i>Cancers</i> , 2023, 15, 485.	3.7	69
1148	Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 740-752.	0.9	15
1149	Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 1066-1079.	0.9	4
1150	Obesity in women's life: role of GLP-1 agonists. <i>Gynecological Endocrinology</i> , 2022, 38, 889-890.	1.7	2
1151	Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. <i>Obesity Reviews</i> , 2023, 24, .	6.5	19
1152	Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. <i>Journal of Clinical Medicine</i> , 2023, 12, 145.	2.4	26
1153	New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. <i>Annual Review of Medicine</i> , 2023, 74, 125-139.	12.2	20



#	ARTICLE	IF	CITATIONS
1154	Medications for the treatment of obesity. <i>Journal of Visceral Surgery</i> , 2023, 160, S12-S14.	0.8	1
1155	Multimodal Care for Diabetes Combining Pharmacotherapy and Metabolic Surgery. , 2023, , 1013-1027.		0
1156	Management of Obesity and Obesity-Related Disorders: From Stem Cells and Epigenetics to Its Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2310.	4.1	6
1159	Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. <i>Nutrients</i> , 2023, 15, 606.	4.1	1
1160	The effects of weightâ€lowering pharmacotherapies on physical activity, function and fitness: A systematic review and metaâ€analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2023, 24, .	6.5	3
1161	The Hypoglycemic and Hypocholesterolemic Activity of <i>Dioscorea deltoidea</i> , <i>Tribulus terrestris</i> and <i>Panax japonicus</i> Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity. <i>Nutrients</i> , 2023, 15, 656.	4.1	4
1163	Suboptimal Weight Loss After Bariatric Surgery: Mechanisms and Treatment Algorithms. , 2023, , 1205-1218.		0
1165	Medical therapy. , 2023, , 353-361.		0
1166	Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. <i>International Journal of Obesity</i> , 0, , .	3.4	1
1167	The Relative Value of Anti-Obesity Medications Compared to Similar Therapies. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 51-62.	1.9	0
1168	Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Children</i> , 2023, 10, 208.	1.5	3
1169	Regulation of adipogenesis by exosomal milk miRNA. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 297-316.	5.7	6
1170	Medical Management of Obesity. , 2023, , 63-81.		0
1171	Etiopathogenesis of Obesity. , 2023, , 15-26.		0
1172	Pharmacologic Treatment of Obesity in Reproductive Aged Women. <i>Current Obstetrics and Gynecology Reports</i> , 2023, 12, 138-146.	0.8	5
1173	Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. <i>Obesity Surgery</i> , 2023, 33, 1017-1025.	2.1	26
1174	Current and emerging medications for the management of obesity in adults. <i>Medical Journal of Australia</i> , 2023, 218, 276-283.	1.7	5
1175	Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.9	2

#	ARTICLE	IF	CITATIONS
1176	Weight Loss for Obstructive Sleep Apnea: Pharmacological and Surgical Management. <i>Journal of Rhinology</i> , 2023, 30, 1-5.	0.2	1
1177	Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review. <i>Journal of Education, Health and Sport</i> , 2023, 18, 23-33.	0.1	0
1178	Contemporary medical, device, and surgical therapies for obesity in adults. <i>Lancet, The</i> , 2023, 401, 1116-1130.	13.7	88
1179	Diagnosis and Management of Prediabetes. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1206.	7.4	59
1180	Obesity and Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 317-339.	3.2	9
1181	Increased meal-induced neurotensin response predicts successful maintenance of weight loss – Data from a randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2023, 143, 155534.	3.4	2
1183	Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets. <i>Molecular Metabolism</i> , 2023, 72, 101718.	6.5	5
1184	Dual gut hormone receptor agonists for diabetes and obesity. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	7
1185	GLP <sup>1</sup> receptor agonists for the treatment of obesity: Role as a promising approach. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	20
1186	Exogenous succinate impacts mouse brown adipose tissue mitochondrial proteome and potentiates body mass reduction induced by liraglutide. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2023, 324, E226-E240.	3.5	6
1187	Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity?. <i>International Journal of Rehabilitation Research</i> , 2023, 46, 14-25.	1.3	1
1188	Pharmacological Support for the Treatment of Obesity – Present and Future. <i>Healthcare (Switzerland)</i> , 2023, 11, 433.	2.0	6
1189	Ischemia with Nonobstructive Coronary Artery Disease and Atrial Cardiomyopathy – Two Sides of the Same Story?. <i>Life</i> , 2023, 13, 443.	2.4	1
1190	Hormonal Gut – Brain Signaling for the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3384.	4.1	8
1191	Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2023, 21, 27-47.	0.8	0
1192	Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 25-45.	3.6	14
1193	Efficacy and safety of Obex <sup>®</sup> in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	2.7	1
1194	Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. <i>Nature Metabolism</i> , 2023, 5, 248-264.	11.9	24

#	ARTICLE	IF	CITATIONS
1195	Clinical characteristics of patients undergoing primary bariatric surgery in the United Kingdom based on the National Bariatric Surgery Registry. <i>Clinical Obesity</i> , 2023, 13, .	2.0	3
1196	Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. <i>Obesity</i> , 2023, 31, 1270-1279.	3.0	14
1197	Pharmaco-endoscopic therapy for weight regain post-gastric bypass: a case report. <i>Journal of Surgical Case Reports</i> , 2023, 2023, .	0.4	0
1198	Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2023, 22, .	6.8	14
1199	Obesity and Kidney Transplantation—How to Evaluate, What to Do, and Outcomes. <i>Transplantation</i> , 0, Publish Ahead of Print, .	1.0	0
1200	Current treatment landscape for obesity in Singapore. <i>Singapore Medical Journal</i> , 2023, 64, 172.	0.6	4
1201	The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	1.9	4
1202	Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. <i>Clinical Therapeutics</i> , 2023, 45, 248-261.	2.5	2
1203	Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2023, 12, 2035.	2.4	2
1204	Impact of <sc>BMI</sc> and comorbidities on efficacy of once-â€‘weekly semaglutide: Post hoc analyses of the <sc>STEP</sc> 1 randomized trial. <i>Obesity</i> , 2023, 31, 990-999.	3.0	3
1205	Fat mass, weight and body shape changes at menopause — causes and consequences: a narrative review. <i>Climacteric</i> , 2023, 26, 381-387.	2.4	3
1207	Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	8
1209	Serious adverse effects following use of liraglutide in individuals with type 2 diabetes. <i>Journal of Diabetology</i> , 2022, 13, 314.	0.3	0
1210	The Fat Kidney. <i>Current Obesity Reports</i> , 0, , .	8.4	0
1211	Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. <i>EClinicalMedicine</i> , 2023, 58, 101882.	7.1	65
1212	Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention. <i>Healthcare (Switzerland)</i> , 2023, 11, 902.	2.0	15
1213	Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 1-24.	3.6	14
1214	Adverse Events of GLP-1 Receptor Agonists for Weight Loss: Twitter and a National Pharmacovigilance Database. , 2023, 2, 41-48.		0

#	ARTICLE	IF	CITATIONS
1215	Novel Anti-Obesity Pharmacotherapies. , 0, , .		0
1216	Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. Nutrition, Metabolism and Cardiovascular Diseases, 2023, , .	2.6	3
1217	A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of <sc>BI</sc> 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Diabetes, Obesity and Metabolism, 2023, 25, 1973-1984.	4.4	4
1218	HÃgado graso (parte 2): enfoque clÃnico y tratamiento. Revista Colombiana De Gastroenterologia, 2023, 38, 46-58.	0.2	0
1219	Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. Molecules, 2023, 28, 3094.	3.8	10
1220	Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double-blind, randomized controlled clinical trial. Experimental and Therapeutic Medicine, 2023, 25, .	1.8	3
1221	New insights into the treatment of obesity. Diabetes, Obesity and Metabolism, 2023, 25, 2058-2072.	4.4	21
1222	Potential contributors to variation in weight-loss response to liraglutide. Obesity Reviews, 2023, 24, .	6.5	1
1223	Tirzepatide: Clinical review of the "etwincretin" injectable. American Journal of Health-System Pharmacy, 2023, 80, 879-888.	1.0	2
1225	Medications for obesity management: Effectiveness and value. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 569-575.	0.9	0
1226	Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Research and Clinical Practice, 2023, 200, 110691.	2.8	14
1227	Liraglutide versus semaglutide for weight reduction" a cost needed to treat analysis. Obesity, 2023, 31, 1510-1513.	3.0	5
1228	Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications. Current Obesity Reports, 2023, 12, 127-146.	8.4	5
1229	A review of the evidence on cardiovascular outcomes from obesity treatment. , 2023, 7, 100071.		3
1230	Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?. Journal of Endocrinological Investigation, 2023, 46, 1761-1774.	3.3	3
1231	Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities. Journal of the National Cancer Institute Monographs, 2023, 2023, 68-76.	2.1	0
1233	Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss. Expert Opinion on Drug Discovery, 2023, 18, 659-669.	5.0	0
1234	Clinical effectiveness of Liraglutide 3.0%mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience. Clinical Obesity, 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
1235	Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data. , 2023, 7, 100072.		0
1236	Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial. Journal of Diabetes Science and Technology, 0, , 193229682311763.	2.2	0
1237	Circulating levels of proglucagonâ€derived peptides are differentially regulated by the glucagonâ€like peptideâ€1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6â€month long interventional study. Diabetes, Obesity and Metabolism, 2023, 25, 2561-2574.	4.4	3
1239	Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Annals of the Rheumatic Diseases, 0, , ard-2023-223845.	0.9	5
1240	Incretin Therapies: Current Use and Emerging Possibilities. , 2023, , 565-580.		0
1241	Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placeboâ€controlled <scp>SCALE</scp> Teens trial. Pediatric Obesity, 2023, 18, .	2.8	2
1242	Obesity: medical management. Medicine, 2023, 51, 509-514.	0.4	0
1243	Obesity and Diabetes: Clinical Aspects. , 2023, , 657-671.		0
1244	Perspectives on weight control in diabetes â€ Tirzepatide. Diabetes Research and Clinical Practice, 2023, 202, 110770.	2.8	4
1246	Role of Glucagonâ€Like Peptideâ€1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. Journal of the American Heart Association, 2023, 12, .	3.7	6
1247	Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Frontiers in Endocrinology, 0, 14, .	3.5	4
1249	A phenotypic approach to obesity treatment. Nutrition in Clinical Practice, 2023, 38, 959-975.	2.4	0
1250	Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake. Journal of the Endocrine Society, 2023, 7, .	0.2	2
1251	The key role of inflammation in the pathogenesis and management of obesity and CVD. Metabolism: Clinical and Experimental, 2023, 145, 155627.	3.4	1
1252	Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? A review. , 2023, 7, 100076.		3
1253	Liraglutide ameliorates hepatic steatosis via retinoic acid receptorâ€related orphan receptor Î±â€mediated autophagy pathway. IUBMB Life, 2023, 75, 856-867.	3.4	0
1254	Obesity and Chronic Disease. , 2023, , 19-27.		1
1255	Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 16, 1767-1774.	2.4	2

#	ARTICLE	IF	CITATIONS
1256	Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational "Real-Life" Study. <i>Nutrients</i> , 2023, 15, 2740.	4.1	1
1257	The use of cellulose, chitosan and hyaluronic acid in transdermal therapeutic management of obesity: A review. <i>International Journal of Biological Macromolecules</i> , 2023, 244, 125374.	7.5	4
1258	Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10164.	4.1	2
1259	Current and future pharmacotherapies for obesity in children and adolescents. <i>Nature Reviews Endocrinology</i> , 2023, 19, 534-541.	9.6	4
1260	GLP-1 agonists for people living with HIV and obesity, is there a potential?. <i>HIV Medicine</i> , 2023, 24, 1029-1034.	2.2	3
1261	Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10449.	4.1	11
1262	Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. <i>New England Journal of Medicine</i> , 2023, 389, 877-888.	27.0	61
1263	Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. <i>Journal of Obesity and Metabolic Syndrome</i> , 2023, 32, 106-120.	3.6	6
1264	2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2023, 41, 1874-2071.	0.5	267
1265	Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2023, 39, .	4.0	0
1266	Involvement of the vagus nerve in the anorectic effect of monoacylglycerol acyltransferase 2 inhibition in mice. <i>Obesity Science and Practice</i> , 2023, 9, 601-608.	1.9	0
1267	Obesity and diabetes. <i>Diabetes Research and Clinical Practice</i> , 2023, 202, 110773.	2.8	10
1268	Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	2
1269	All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2897-2909.	4.4	5
1270	Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice. <i>Psychopharmacology</i> , 2023, 240, 1287-1298.	3.1	0
1271	Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2023, 5, 49-53.	0.1	0
1272	Current pharmacological approaches in obesity treatment. , 2023, 3, 32-48.		0
1273	Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8592.	4.1	2

#	ARTICLE	IF	CITATIONS
1274	Individualised prescription of medications for treatment of obesity in adults. <i>Reviews in Endocrine and Metabolic Disorders</i> , 0, , .	5.7	1
1275	Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice. <i>Neuroscience Letters</i> , 2023, 808, 137299.	2.1	0
1276	Obesity management for cardiovascular disease prevention. , 2023, 7, 100069.		3
1277	Perivascular adipose tissue in vascular pathologiesâ€”a novel therapeutic target for atherosclerotic disease?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	4
1278	Gut hormone co-agonists for the treatment of obesity: from bench to bedside. <i>Nature Metabolism</i> , 2023, 5, 933-944.	11.9	15
1279	Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2023, 402, 613-626.	13.7	73
1280	Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and postâ€”bariatric treatment failure. <i>Clinical Obesity</i> , 2023, 13, .	2.0	6
1281	Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions. <i>Archives of Endocrinology and Metabolism</i> , 2023, 67, .	0.6	2
1282	Targeting the central melanocortin system for the treatment of metabolic disorders. <i>Nature Reviews Endocrinology</i> , 2023, 19, 507-519.	9.6	4
1283	Tripleâ€”Hormone-Receptor Agonist Retatrutide for Obesity â€” A Phase 2 Trial. <i>New England Journal of Medicine</i> , 2023, 389, 514-526.	27.0	143
1284	Poria cocos compounds targeting neuropeptide Y1 receptor (Y1R) for weight management: A computational ligand- and structure-based study with molecular dynamics simulations identified beta-amyrin acetate as a putative Y1R inhibitor. <i>PLoS ONE</i> , 2023, 18, e0277873.	2.5	0
1285	Shorter History of Hypertension as a Predictor of Hypertension Remission after 3-years of Bariatric Surgery: Data from the GATEWAY Trial. <i>Obesity Surgery</i> , 2023, 33, 2485-2492.	2.1	0
1286	Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines. <i>Journal of Clinical Medicine</i> , 2023, 12, 4431.	2.4	4
1287	Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. <i>Aesthetic Surgery Journal</i> , 2023, 44, 60-67.	1.6	17
1288	GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	2
1289	Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 109, e1-e11.	3.6	1
1290	Tratamento farmacolÃ³gico para obesidade no Brasil: drogas disponÃ­veis, eficÃ¡cia e custos associados. , 2023, 3, 55-62.		0
1291	Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection. <i>Canadian Journal of Cardiology</i> , 2023, 39, 1816-1838.	1.7	2



#	ARTICLE	IF	CITATIONS
1292	The Management of Obesity in 2023: An Update. , 0, , .		0
1293	Is combined exercise and incretin-based therapy the way forward for weight-loss maintenance?. Nature Reviews Endocrinology, 0, , .	9.6	0
1294	The Fatty Kidney and Beyond: A Silent Epidemic. American Journal of Medicine, 2023, 136, 965-974.	1.5	2
1297	Correcting calculation and data errors reveals that the original conclusions were incorrect in "The best drug supplement for obesity treatment: a systematic review and network meta-analysis". Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	0
1298	Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia " A Narrative Review. Drugs and Aging, 2023, 40, 703-719.	2.7	6
1300	Liraglutide pretreatment attenuates sepsis-induced acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 325, L368-L384.	2.9	3
1301	Blockbuster Medications for Obesity: A Primer for Nephrologists. American Journal of Kidney Diseases, 2023, 82, 762-771.	1.9	0
1302	Should Prediabetes be Treated Pharmacologically?. Diabetes Therapy, 2023, 14, 1585-1593.	2.5	1
1303	Low Perception of Obesity as a Pathological Condition Among Italian Cardiologists. High Blood Pressure and Cardiovascular Prevention, 2023, 30, 351-356.	2.2	1
1304	Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery. JAMA Surgery, 2023, 158, 1003.	4.3	18
1305	The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia, 2023, 66, 1846-1858.	6.3	6
1306	Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	4
1307	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Journal of the American College of Cardiology, 2023, 82, 833-955.	2.8	48
1308	Incretin Analogs for Weight Management in Adults Without Diabetes. Annals of Pharmacotherapy, 0, , .	1.9	0
1309	Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon. Journal of Arthroplasty, 2024, 39, 38-43.	3.1	1
1310	Future therapies for obesity. Clinical Medicine, 2023, 23, 337-346.	1.9	4
1311	Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work. Journal of Cardiovascular Development and Disease, 2023, 10, 327.	1.6	0
1312	Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus. Primary Care Diabetes, 2023, , .	1.8	0

#	ARTICLE	IF	CITATIONS
1313	The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. <i>American Journal of Clinical Nutrition</i> , 2023, 118, 614-626.	4.7	4
1314	Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 109, 279-292.	3.6	1
1315	US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	2
1316	Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy. <i>Obesity Science and Practice</i> , 2024, 10, .	1.9	1
1317	A narrative review of approved and emerging anti-obesity medications. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 101757.	2.7	4
1318	GLP-1 analogue as a novel approach for fertility treatment: unravelling the therapeutic potential: A narrative review. <i>Obstetrics &amp; Gynecology International Journal</i> , 2023, 14, 120-122.	0.1	0
1319	Down the Rabbit Hole: Reviewing the Evidence for Primary Prevention of Cardiovascular Disease in People with Obesity. <i>European Journal of Preventive Cardiology</i> , 0, , .	1.8	0
1320	Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3560-3577.	4.4	3
1321	Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake. <i>International Journal of Obesity</i> , 2023, 47, 1143-1151.	3.4	1
1322	Effect on Weight Loss of an Oral Supplement Containing Cinnamon Bark ( <i>Cinnamomum cassia</i> ) and <i>Withania somnifera</i> in Adult Patients with Overweight and Obesity: A Pilot Study. <i>J</i> , 2023, 6, 508-516.	0.9	0
1323	The promise of a new orally active body weight reducer. <i>European Heart Journal</i> , 2023, 44, 3403-3404.	2.2	0
1324	Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
1325	Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
1326	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2023, 148, .	1.6	84
1327	Peptide drugs application in metabolic diseases and discovery strategies. , 2022, 3, 24-31.		0
1328	Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study. <i>Obesity Surgery</i> , 2023, 33, 2941-2944.	2.1	0
1329	Metabolic and Bariatric Endoscopy: A Mini-Review. <i>Life</i> , 2023, 13, 1905.	2.4	1
1330	A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. <i>International Journal of Obesity</i> , 2023, 47, 1224-1231.	3.4	0

#	ARTICLE	IF	CITATIONS
1331	EMBIO trial study protocol: left gastric artery embolisation for weight loss in patients living with obesity with a BMI 35â€“50 kg/m <sup>2</sup> </sup>. <i>BMJ Open</i> , 2023, 13, e072327.	1.9	0
1332	The Role of Endoscopy in the Management of Adolescent Bariatric Patients: A Primer For Pediatric Gastroenterologists. <i>Current Gastroenterology Reports</i> , 0, , .	2.5	0
1333	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. <i>Nature Medicine</i> , 2023, 29, 2909-2918.	30.7	26
1334	When There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity. <i>Transplant International</i> , 0, 36, .	1.6	0
1335	Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. , 2023, 251, 108549.		3
1337	Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?. <i>Sleep</i> , 2023, 46, .	1.1	2
1338	Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery. <i>Metabolism: Clinical and Experimental</i> , 2023, 148, 155689.	3.4	7
1340	Pharmacotherapy of Obesity: An Updated Overview. <i>Journal for Nurse Practitioners</i> , 2023, 19, 104750.	0.8	0
1341	High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	1
1342	Pharmacotherapy before and after bariatric surgery. <i>Metabolism: Clinical and Experimental</i> , 2023, 148, 155692.	3.4	5
1343	Strategies for Long-Term Weight Loss and Maintenance. <i>Korean Journal of Family Practice</i> , 2023, 13, 128-137.	0.3	0
1344	The Effective Use of Anti-obesity Medications. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0
1346	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
1347	Waist circumference and glycaemia are strong predictors of progression to diabetes in individuals with prediabetes in sub-Saharan Africa: 4-year prospective cohort study in Malawi. <i>PLOS Global Public Health</i> , 2023, 3, e0001263.	1.6	1
1348	Gut Hormones and Metabolic Syndrome. , 2023, , 1-16.		0
1349	Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2023, , 119-126.	0.6	0
1350	Intermittent fasting for the prevention of cardiovascular disease: implications for clinical practice. <i>British Journal of Cardiac Nursing</i> , 2023, 18, 1-9.	0.1	0
1351	Management of Medication-Induced Weight Gain. <i>Gastroenterology Clinics of North America</i> , 2023, , .	2.2	0

#	ARTICLE	IF	CITATIONS
1352	Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future. <i>Lancet Diabetes and Endocrinology</i> , 2023, 11, 861-878.	11.4	5
1353	Severe hypertriglyceridemia: Existing and emerging therapies. , 2023, 251, 108544.		3
1354	Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2023, 149, 155710.	3.4	5
1355	Fatty Acids Increase GDF15 and Reduce Food Intake Through a GFRAL Signaling Axis. <i>Diabetes</i> , 2024, 73, 51-56.	0.6	1
1358	Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases. <i>Current Cardiology Reports</i> , 0, , .	2.9	0
1359	Retatrutide: a triple incretin receptor agonist for obesity management. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 1003-1008.	4.1	0
1360	Navigating the Role of Anti-Obesity Agents Prior to Pregnancy: A Narrative Review. <i>Seminars in Reproductive Medicine</i> , 0, , .	1.1	0
1361	Enteroendocrine cell regulation of the gut-brain axis. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	4
1362	Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based coagonists. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1363	Anti-obesity pharmacotherapy in adults with chronic kidney disease. <i>Kidney International</i> , 2023, , .	5.2	1
1364	Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 690-698.	4.4	0
1365	Obtaining long-term recovery: advances in optimizing treatment outcomes in patients with binge-eating disorder. <i>Expert Review of Neurotherapeutics</i> , 2023, 23, 1097-1111.	2.8	0
1366	What Is Food Noise? A Conceptual Model of Food Cue Reactivity. <i>Nutrients</i> , 2023, 15, 4809.	4.1	1
1367	Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management. <i>Cell Reports Medicine</i> , 2023, 4, 101292.	6.5	0
1368	Study protocol of a clinical randomized controlled trial on the efficacy of an innovative Digital thErapy to proMote wEIGHT loss in patients with obesity by incReasing their Adherence to treatment: the DEMETRA study. <i>Frontiers in Digital Health</i> , 0, 5, .	2.8	0
1369	Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population. <i>Cureus</i> , 2023, , .	0.5	0
1370	[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. <i>Actas Dermo-sifilograficas</i> , 2023, , .	0.4	0
1371	GORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists. <i>Gut</i> , 2024, 73, 211-212.	12.1	0

#	ARTICLE	IF	CITATIONS
1373	Intersections between HIV and obesity in emerging economies. <i>Current Opinion in HIV and AIDS</i> , 2024, 19, 35-44.	3.8	0
1374	Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 319-328.	4.4	3
1375	Impact of a pharmacist-led weight management service in a cardiology clinic. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2024, 64, 557-563.	1.5	0
1376	The efficacy of liraglutide combined with intragastric balloon on weight loss. <i>Revista Da Associação Médica Brasileira</i> , 2023, 69, .	0.7	0
1377	The cardiovascular effects of novel weight loss therapies. <i>European Heart Journal</i> , 2023, 44, 5036-5048.	2.2	5
1378	Obesity and Dyslipidemia. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
1379	Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism. <i>MedComm</i> , 2023, 4, .	7.2	0
1380	Seeking satiety: From signals to solutions. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	0
1381	Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond. <i>Metabolism: Clinical and Experimental</i> , 2024, 151, 155741.	3.4	1
1382	Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide. <i>Farmatsiya I Farmakologiya</i> , 2023, 11, 255-276.	0.6	1
1383	The relation between excess adiposity and breast cancer in women: Clinical implications and management. <i>Critical Reviews in Oncology/Hematology</i> , 2024, 193, 104213.	4.4	0
1384	Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. <i>European Journal of Internal Medicine</i> , 2023, , .	2.2	4
1385	Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. <i>Endocrine Practice</i> , 2024, 30, 160-171.	2.1	3
1386	Obesity Management in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 330, 2000.	7.4	8
1387	Liraglutide 3.0mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit. <i>Eating and Weight Disorders</i> , 2023, 28, .	2.5	0
1388	Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2024, 326, G120-G132.	3.4	1
1389	Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 891-900.	4.4	1
1390	Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. <i>Medicina Clínica</i> , 2024, 162, 118-122.	0.6	1

#	ARTICLE	IF	CITATIONS
1391	Size matters: the biochemical logic of ligand type in endocrine crosstalk. , 2024, 3, .		0
1392	Drug Therapies for Diabetes. International Journal of Molecular Sciences, 2023, 24, 17147.	4.1	1
1395	Early and later stage persistence with antiobesity medications: A retrospective cohort study. Obesity, 2024, 32, 486-493.	3.0	2
1396	Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development. Experimental Biology and Medicine, 0, , .	2.4	0
1397	Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation. Transplantation, 0, , .	1.0	0
1398	Antiobesity pharmacotherapy to facilitate living kidney donation. American Journal of Transplantation, 2024, 24, 328-337.	4.7	0
1399	Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA - Journal of the American Medical Association, 2024, 331, 38.	7.4	21
1400	MASLD treatment—a shift in the paradigm is imminent. Frontiers in Medicine, 0, 10, .	2.6	0
1401	Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss. Aesthetic Surgery Journal, 0, , .	1.6	0
1403	Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges. Drugs, 2024, 84, 127-148.	10.9	0
1404	Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet. Journal of Clinical Gastroenterology, 0, , .	2.2	0
1405	Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study. Annals of the American Thoracic Society, 2024, 21, 464-473.	3.2	0
1406	Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Failure, 0, , .	3.1	0
1407	Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study). Diabetes, Obesity and Metabolism, 0, , .	4.4	1
1408	Glucagon-like peptide agonists: A prospective review. Endocrinology, Diabetes and Metabolism, 2024, 7, .	2.4	1
1409	Effect of Liraglutide on Weight Loss and BMI Among Patients Who Are Overweight and Obese with Type 2 Diabetes: A Systematic Review and Meta-analysis. European Medical Journal (Chelmsford,) Tj ETQq1 1 0.784304 rgBT (Overlook		
1410	Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity. Cureus, 2023, , .	0.5	0
1411	Efficacy of noigliutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes, Obesity and Metabolism, 2024, 26, 1057-1068.	4.4	0

#	ARTICLE	IF	CITATIONS
1412	A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. <i>Endocrine Practice</i> , 2024, 30, 292-303.	2.1	0
1413	Consensus on pharmacological treatment of obesity in Latin America. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1415	Impact of GLP-1 Agonists on Male Reproductive Healthâ€”A Narrative Review. <i>Medicina (Lithuania)</i> , 2024, 60, 50.	2.0	1
1416	Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
1417	Weight Loss Interventions for Adults With Obesity-Related Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2024, 12, 840-847.	3.8	1
1418	Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 0, , .	4.8	0
1419	Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis. <i>European Psychiatry</i> , 2023, 66, .	0.2	4
1420	Pharmacotherapy for obesity: moving towards efficacy improvement. <i>Diabetology and Metabolic Syndrome</i> , 2024, 16, .	2.7	0
1421	Weight Loss Following Bariatric Surgery in People with or without Metabolic Syndrome: A 5-Year Observational Comparative Study. <i>Journal of Clinical Medicine</i> , 2024, 13, 256.	2.4	0
1422	Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?. <i>Pharmacological Research</i> , 2024, 200, 107058.	7.1	0
1423	Chronic Kidney Disease and Obesity. <i>Nephron</i> , 2023, 147, 660-664.	1.8	1
1424	Review article: Pharmacologic management of obesity â€”updates on approved medications, indications and risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 475-491.	3.7	0
1425	Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?. <i>Journal of Arthroplasty</i> , 2024, 39, 277-282.	3.1	0
1426	Glucagon-like Peptide-1 Agonists. <i>JBJS Reviews</i> , 2024, 12, .	2.0	0
1427	Recent advances in peptide-based therapies for obesity and type 2 diabetes. <i>Peptides</i> , 2024, 173, 171149.	2.4	1
1428	Suicidality among users of glucagonâ€”like peptideâ€”1 receptor agonists: An emerging signal?. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1150-1156.	4.4	1
1429	Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. <i>Current Problems in Cardiology</i> , 2024, 49, 102403.	2.4	0
1430	2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2024, 16, .	2.7	0



#	ARTICLE	IF	CITATIONS
1431	Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 1346-1354.	4.4	1
1432	Role of newer anti-diabetes drugs in prediabetes: A systematic review. , 2024, , 393-406.		0
1433	Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. <i>International Journal of Clinical Pharmacy</i> , 2024, 46, 488-495.	2.1	0
1435	Gut Hormones and Metabolic Syndrome. , 2023, , 357-372.		0
1437	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
1438	Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review. <i>Sci</i> , 2024, 6, 9.	3.0	0
1439	Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?. <i>Expert Opinion on Pharmacotherapy</i> , 2024, 25, 131-138.	1.8	0
1440	Obesity and Overweight: The "Elephant in the Room" That We can No Longer Ignore: Time to SELECT Treatments. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2024, 31, 3-6.	2.2	0
1441	Chondroitin Sulfate-Derived Micelles for Adipose Tissue-Targeted Delivery of Celastrol and Phenformin to Enhance Obesity Treatment. <i>ACS Applied Bio Materials</i> , 2024, 7, 1271-1289.	4.6	0
1442	Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease. <i>Biomedicines</i> , 2024, 12, 363.	3.2	0
1443	Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index $\geq 27$ kg/m <sup>2</sup> : SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. <i>Hypertension</i> , 2024, 81, .	2.7	1
1444	Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2024, 12, 162-173.	11.4	3
1445	The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. <i>Patient Preference and Adherence</i> , 0, Volume 18, 373-382.	1.8	1
1446	Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0
1447	Effect of YC-1102 on the Improvement of Obesity in High-Fat Diet-Induced Obese Mice. <i>Current Issues in Molecular Biology</i> , 2024, 46, 1437-1450.	2.4	0
1449	Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. <i>Medicina Clínica (English Edition)</i> , 2024, 162, 118-122.	0.2	0
1450	The vagus nerve mediates the physiological but not pharmacological effects of PYY3-36 on food intake. <i>Molecular Metabolism</i> , 2024, 81, 101895.	6.5	0
1451	Obesity management: sex-specific considerations. <i>Archives of Gynecology and Obstetrics</i> , 2024, 309, 1745-1752.	1.7	0

#	ARTICLE	IF	CITATIONS
1452	Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. <i>Frontiers in Endocrinology</i> , 0, 15, .	3.5	0
1453	Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity. <i>Nutricion Hospitalaria</i> , 2024, , .	0.3	0
1454	Semaglutide 2.4Âmg clinical outcomes in patients with obesity or overweight in a realâ€world setting: A 6â€month retrospective study in the United States (SCOPE). <i>Obesity Science and Practice</i> , 2024, 10, .	1.9	0
1455	Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0Âmg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial. <i>Lancet Regional Health - Europe</i> , The, 2024, 39, 100853.	5.6	0
1456	G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?. <i>Biomedicine and Pharmacotherapy</i> , 2024, 172, 116245.	5.6	0
1457	The double burden: Navigating type 1 diabetes and obesity. <i>Clinical Obesity</i> , 0, , .	2.0	0
1458	What is the evidence regarding the safety of new obesity pharmacotherapies. <i>International Journal of Obesity</i> , 0, , .	3.4	0
1459	The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. <i>Endocrinology and Metabolism</i> , 2024, 39, 12-22.	3.0	0
1460	A Federated Database for Obesity Research: An IMI-SOPHIA Study. <i>Life</i> , 2024, 14, 262.	2.4	0
1461	Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitorsâ€”protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). <i>Trials</i> , 2024, 25, .	1.6	0
1462	Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. <i>EClinicalMedicine</i> , 2024, 69, 102475.	7.1	0
1463	Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice. <i>Endocrine</i> , 0, , .	2.3	0
1464	GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. <i>Gastroenterology Insights</i> , 2024, 15, 191-212.	1.2	0
1465	Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 2521-2523.	4.4	0
1466	Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing Ablation for Atrial Fibrillation (GOAL-AF) protocol. <i>Pilot and Feasibility Studies</i> , 2024, 10, .	1.2	0
1467	Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight. <i>Diabetes Research and Clinical Practice</i> , 2024, 209, 111593.	2.8	0
1468	Orforglipron, a novel nonâ€peptide oral daily glucagonâ€like peptideâ€1 receptor agonist as an antiâ€obesity medicine: A systematic review and metaâ€analysis. <i>Obesity Science and Practice</i> , 2024, 10, .	1.9	0
1470	Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review. <i>Obesity Surgery</i> , 2024, 34, 1846-1854.	2.1	0

#	ARTICLE	IF	CITATIONS
1471	Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy. <i>Human Cell</i> , 2024, 37, 666-674.	2.7	0
1473	Weight-centric prevention of cancer. , 2024, 10, 100106.		0
1475	Obesity and Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2024, 132, 232-239.	1.2	0
1476	Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. <i>International Journal of Obesity</i> , 0, , .	3.4	0
1477	Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn. <i>International Journal of Obesity</i> , 0, , .	3.4	0
1478	Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials. <i>Obesity Reviews</i> , 0, , .	6.5	0
1479	Obesity: the perfect storm for heart failure. <i>ESC Heart Failure</i> , 0, , .	3.1	0
1480	Glucagon-like peptide-1 analogs: Miracle drugs are blooming?. <i>European Journal of Medicinal Chemistry</i> , 2024, 269, 116342.	5.5	0
1481	Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice. <i>Drug Design, Development and Therapy</i> , 0, Volume 18, 845-858.	4.3	0
1482	Effect and safety of electroacupuncture on weight loss in obese patients with pre-diabetes: study protocol of a randomised controlled trial. <i>BMJ Open</i> , 2024, 14, e075873.	1.9	0
1483	Approach to Obesity Treatment in Primary Care. <i>JAMA Internal Medicine</i> , 0, , .	5.1	0
1485	Could semaglutide promote lifestyle interventions? Influence of semaglutide among people living with overweight/obesity on weight loss and physical activity in a real-world scenario. , 0, , .		0
1487	Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2024, 34, 1653-1664.	2.1	0
1488	Practical strategies to manage obesity in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 2029-2045.	4.4	0
1489	Next Generation Weight Loss Drugs for the Prevention of Cancer?. <i>Cancer Control</i> , 2024, 31, .	1.8	0
1490	Effectiveness and safety of drugs for obesity. <i>BMJ, The</i> , 0, , e072686.	6.0	0
1491	GLP-1 Receptor Agonists and Gastrointestinal Adverse Eventsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2024, 331, 885.	7.4	0
1492	Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. <i>Diabetes, Obesity and Metabolism</i> , 2024, 26, 2209-2228.	4.4	0